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Adrenal glucocorticoids are major modulators of multiple functions, including energy metabolism, stress re-
sponses, immunity, and cognition. The endogenous secretion of glucocorticoids is normally characterized by a
prominent and robust circadian (around 24 hours) oscillation, with a daily peak around the time of the habitual
sleep-wake transition and minimal levels in the evening and early part of the night. It has long been recognized
that this 24-hour rhythm partly reflects the activity of a master circadian pacemaker located in the supra-
chiasmatic nucleus of the hypothalamus. In the past decade, secondary circadian clocks based on the same
molecular machinery as the central master pacemaker were found in other brain areas as well as in most pe-
ripheral tissues, including the adrenal glands. Evidence is rapidly accumulating to indicate that misalignment
between central and peripheral clocks has a host of adverse effects. The robust rhythm in circulating gluco-
corticoid levels has been recognized as a major internal synchronizer of the circadian system. The present review
examines the scientific foundation of these novel advances and their implications for health and disease pre-
vention and treatment. (Endocrine Reviews 38: 3–45, 2017)
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I. Introduction
A. Previous understanding of circadian rhythms
Since the discovery of the 24-hour variations of excretedketosteroids by G. Pincus in the early 1940s (1) and later
of the daily rhythm of plasma glucocorticoid (GC) levels in
both humans and laboratory rodents (2, 3), an abundant
literature has documented that the daily variation of circu-
lating GCs is perhaps the largest and most robust circadian
rhythm of all blood constituents in mammals. Although the
multiple actions of GCs on immunity, inflammation, meta-
bolism, cognitive function, mood, growth, reproduction, and
cardiovascular function andon the stress response (seeBox1)
are well recognized, the functional significance of the wide
daily variation of their circulating levels for these multiple
functions and for the circadian timing system itself has only
begun to be understood. As will be detailed below, daily
rhythmicity is regulatedatdifferent levels of thehypothalamo-
pituitary-adrenal (HPA) axis. In turn, circulating GCs are
internal time-givers that can affect the circadian organization
ofmanyperipheral organs aswell as ofmultiple brain regions.
In humans, the main GC is cortisol, whereas corticosterone
circulates in a 10-fold lower concentration. In contrast, in
rodents, corticosterone is the primary GC.
Circadian rhythms (fromLatin“circa”meaning “about,”
and “dies”meaning “day”) in physiological and behavioral
processes are a ubiquitous feature in living organisms. Cir-
cadian rhythms are not just a passive response to daily cyclic
fluctuations in the environment, but instead rely on
ESSENTIAL POINTS
· The daily rhythmicity of plasma glucocorticoid (GC) levels is a strong modulator ofmany physiological and psychological processes, although its functional significance
is poorly understood.
· The suprachiasmic nuclei of the hypothalamus have been shown to harbora molecular clock mechanism generating circadian rhythmicity in mammals, but the
same mechanism is present in many peripheral tissues and elsewhere in the brain.
· Mineralocorticoid receptors and glucocorticoid receptors mediate the action ofnaturally occurring GC in complementary fashion.
· Optimal physiological effects of GC occur when the central signal that controls therhythm of GC release and the peripheral rhythms in tissues expressing GC receptors
are aligned.
· New studies suggest that misalignment of central and peripheral oscillators mayincrease the risk of disease, with adverse effects on the immune system,
cardiovascular system and metabolism, among others prominent.
· Chronopharmacological strategies that attempt to normalize the rhythm of circulatingGCs have potential to improve the treatment of a wide variety of physical and mental
conditions.
4 Oster et al Functional Significance of Glucocorticoid Rhythm Endocrine Reviews, February 2017, 38(1):3–45
endogenous, self-sustained clocks and, thus, persist under
constant environmental conditions. In the literature, several
terms are often used interchangeably when referring to
variations with a period of close to 24 hours. For the sake of
clarity, in the present review, we will restrict the use of the
term “circadian” to rhythms controlled, at least partly, by
endogenous clocks. When the origin of a rhythm is clearly
exogenous or its control by an endogenous clockmechanism
is still unproven, we will use the term “daily rhythm” or
“24-hour rhythm.” Lastly, we will use the term “diurnal” to
indicate “daytime” as opposed to “nighttime” or “noctur-
nal” as, for example, to refer to “diurnal” vs “nocturnal”
species. Clock-controlled mechanisms allow anticipatory
temporal organization of biological functions according to
predictable changes (eg, the daily
light-dark cycle) and, just as
importantly, a temporal segrega-
tion between conflicting or in-
compatible processes (eg, feeding
and sleeping). After pioneer studies
showing that bilateral damage to
the suprachiasmatic nuclei (SCN)
of the hypothalamus results in the
disappearance of daily rhythmicity
of plasma corticosterone, drinking
behavior, and rest-activity in rats
(14, 15), much experimental work
has confirmed that the SCN
harbors a self-sustained clock play-
ing an essential role for the mainte-
nance of circadian rhythmicity in
mammals. Even when isolated from
the rest of the brain, the SCN clock
continues to oscillate (16). Further-
more, transplantation of fetal SCN
cells can restore the rest-activity
rhythm in adult animals rendered
arrhythmic by SCN lesions (17).
For a while, the SCN was thus
viewed as the single self-sustained
pacemaker that drives internal
rhythmicity, entraining “slave” os-
cillators in other tissues (18). A
schematic representation of the view
of the mammalian circadian system
that prevailed until the early 1990s
is given in Figure 1 (19).
B. Recent advances and
implications for health anddisease
Starting around the turn of the
millennium, an increasing amount
of experimental evidence has chal-
lenged the monopoly of the SCN clock as endogenous cir-
cadian pacemaker. In particular, it has been shown that
many peripheral tissues are capable of generating self-
sustained oscillations when isolated in vitro and can be
synchronized by external or internal cues, independently of
the master SCN clock. Therefore, the physiological regula-
tion of circadian rhythms is now thought to involve a
multioscillatory system, comprising a master circadian
pacemaker in the SCN and numerous secondary clocks in
other cerebral regions and in most peripheral organs, in-
cluding endocrine glands (20). Figure 2 illustrates the con-
temporary view of the mammalian circadian system. The
molecular mechanisms generating circadian rhythmicity
within pacemaker neurons of the SCN have been identified
Box 1. The Stress Concept
Stress was defined by Hans Selye (4) as “a state of nonspecific tension in living
matter, which manifests itself by tangible morphologic changes in various organs
and particularly in the endocrine glands which are under anterior pituitary
control.” This “state of stress” is evoked by a stressor, which is defined as any
stimulus that disrupts cellular “homeostasis” or, on the organismic level, as “a
real or interpreted threat to the physiological and psychological integrity” (5, 6).
Processing of stressful information occurs in the central nervous system via
different pathways. Physical (sensory) stressors (heat, cold, injury, immune
activation) are communicated directly from the brain stem to the hypothalamus.
Psychological stressors either real or imagined are processed in higher brain
regions and reach the hypothalamus via multisynaptic pathways. In the hypo-
thalamic paraventricular nucleus (PVN), the processed stressful information
activates the sympathetic nervous system and HPA axis, which coordinate the
organism’s defense reactions with the goal to restore homeostasis and to promote
(behavioral) adaptation. The principal conductor of the stress response is
corticotropin-releasing hormone (CRH) together with a cocktail of secreta-
gogues, notably vasopressin. The activation of the HPA axis and its GC end-
product occurs over a background of circadian and ultradian variations (7).
GCs are secreted late in the stress response and usually reach maximum levels
after 15minutes of exposure. “Glucocorticoids acting via glucocorticoid receptors
(GR) prevent initial stress reactions (eg, autonomic, immune, inflammatory,
metabolic, brain) fromovershooting and becomingdamaging themselves” (8). The
action via mineralocorticoid receptors (MRs) is opposite and enhances the initial
stress reaction (9, 10) (see Box 2).
Coping. Some researchers rather restrict the definition of stress entirely to
a psychological construct because every stressor, even the physical ones, is also
processed in higher brain regions “under conditions where an environmental
demand exceeds the regulatory and adaptive capacity of an organism, in par-
ticular in case of unpredictability and uncontrollability” (11). The most stressful
condition is: no information, no control, and no prediction of upcoming events,
with an uncertain feeling of threat. A safe place, social context, and self-esteem
help one to cope (12). It is not so much what happens but rather how the in-
dividual interprets the situation and copes. It emphasizes the importance of
anticipation and appraisal of important information.
Allostasis. The concept of “allostasis” was introduced to describe the condition
when structure and function of brain networks adapt to or even anticipate real or
perceived changes in the environment (6). Allostasis generally occurs as a result of
cumulative stress exposure and describes an unstable equilibrium characterized
by variable set points, as opposed to homeostasis where return to stability is the
ultimate goal. The term “allostatic load” designates the cost of allostasis through
energyconsuming adaptations (13).
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as a complex transcriptional-translational feedback loop.
The same interacting molecular circuitry of core clock ele-
ments and clock-dependent elements is present in multiple, if
not all, peripheral tissues, including heart, kidney, muscle,
liver, pancreas, blood, and fat. Specifically, confirming old
suspicions (21), a circadian clock has been newly discovered
in the adrenal glands andhasbeen shown toparticipate in the
control of the 24-hour rhythmofGCs (22), thereby revealing
anadditional element of circadian control to the regulationof
the HPA axis.
Although the environmental light-dark cycle is the pri-
mary external synchronizer, or zeitgeber, of the master clock
in the SCN, the timing of food intake and fasting has lately
been recognized as a potent synchronizer of peripheral clocks
(Figure 2). The central SCN clock regulates behavioral
rhythms, including the sleep-wake and feeding cycles, and
also entrains peripheral clocks via neural and humoral
mechanisms, including the activity of the two branches of the
autonomous nervous systemand the rhythmic release ofGCs
and melatonin (illustrated in Figure 3). A regular 24-hour
temporal organization is thought to be important for good
health. Laboratory studies manipulating circadian organi-
zation in both humans (23–25) and rodents (26, 27) and a
vast literature on the epidemiology of shift work (28–30)
have documented that misalignment of central and periph-
eral clocks has adverse health consequences. Because GC
receptors (nuclear receptor subfamily 3, group C, member 1,
NR3C1, referred to as GR in the remainder of this text; see
Box 2) are widely distributed both in the central nervous
system and in the periphery, the robust rhythmofGC release
can be viewed as amajor internal synchronizing signal of the
mammalian circadian system (31). In contrast, mineralo-
corticoid receptors (nuclear receptor subfamily 3, group C,
member 2, NR3C2; referred to as MRs in the remainder of
this text) no longer respond when levels of GC are elevated
above basal values and therefore do not mediate circadian
modulation of target tissue activity (see Box 2). A corollary
of this concept is that alterations in the 24-hour rhythm of
GC levels may promote circadian misalignment and its ad-
verse health consequences. Multiple studies have shown that
the 24-hour profile of cortisol concentrations does not adapt
rapidly to acute shifts in light-dark, activity-rest and/or
feeding cycles, as occur in jet lag and shift work rotations,
although its amplitude may be reduced under some condi-
tions (32). Under such conditions, the misalignment of the
24-hour cortisol rhythm causes or exacerbates a lack of
synchronization between central and peripheral clocks.
Pathological conditions where cortisol production is either
excessive or insufficient are associated with profound alter-
ations of the 24-hour profile of peripheral concentrations.
Under such conditions, the synchronizing signal provided by
the 24-hour rhythm of GC concentrations is disrupted,
potentially leading to a reduction in the overall alignment of
the circadian system and adverse health consequences. For
example, in patients with adrenal insufficiency, the failure to
restore a normal GC profile by current regimens of re-
placement therapymaybepartly responsible for thedoubling
of the age-adjusted mortality risk (33) and for the severe
mental and physical fatigue with many patients remaining
unfit for work (34). Chronopharmacological strategies that
attempt to normalize the rhythmof circulatingGCsmay thus
help to improve the efficacy of treatment and prevent or
reduce complications.
C. Aims and structure of the review
The overall goals of the present review are to provide an
update on the circadian organization of the mammalian
system, todiscuss the roleof the24-hour rhythmof circulating
GCs as a major internal synchronizer of central and
Figure 1.
Figure 1. Schematic conceptual representation of the mammalian
circadian system as it was understood circa 1990. A circadian
pacemaker located in the SCN of the hypothalamus was widely
thought to be the only self-sustained 24-hour clock and to act as
master pacemaker for the entire organism. The molecular
mechanism generating the self-sustained central circadian signal
was not known. The light-dark cycle had been recognized as the
main external synchronizer (zeitgeber) of the master pacemaker, but
inputs from social cues and physical activity had also been
identified. A few peripheral tissues—including the adrenals—had
been found to generate damped oscillations that require input from
the master pacemaker to be sustained (“slave” oscillators). Most
peripheral tissues were considered not capable of generating self-
sustained circadian oscillations and were thought to be passively
entrained by the master pacemaker (“passive slaves”). The 24-hour
rhythm of circulating GCs was seen as an “overt” rhythm reflecting
central circadian timing, with inputs modifying its wave shape
elicited by external and internal stimuli. [Redrawn and modified
from E. Van Cauter and J. Aschoff: Endocrine and other biological
rhythms. In: DeGroot LJ, ed. Endocrinology. Vol 3. WB Saunders;
Philadelphia, PA: 1989; 2658–2705 (19), with permission.]
6 Oster et al Functional Significance of Glucocorticoid Rhythm Endocrine Reviews, February 2017, 38(1):3–45
peripheral clocks, and to derive the implications of abnor-
malities of this rhythm for health and disease. The article will
start with a brief description of how the multioscillatory
circadian systemdrives rhythmicity of physiological processes
in the brain and peripheral tissues and then summarize the
current understandingof the control of the24-hour rhythmof
circulating GC levels and modulatory influences by external
and internal factors. After a short overview of the multiple
physiological actions of GCs, human conditions where ab-
normalities of the 24-hour profile of cortisol have been
identified will be discussed, and their implications for car-
diometabolic risk, central nervous system function, and
quality of life will be extrapolated. Finally, we will examine
the potential therapeutic implications of correcting or re-
storing this internal synchronizing signal.
II. The Organization of the Mammalian
Circadian System
A. Central and peripheral circadian clocks
Rhythmic regulation of physiology and behavior on a
daily basis is shared across phylogenetic kingdoms and relies
on a complex system of cellular clocks with endogenous
periods close to 24 hours. These cellular clocks are syn-
chronized by multiple inputs, and their outputs deliver local
as well as widely distributed temporal information. In
mammals, circadian clocks are found in various brain and
peripheral tissues, including the adrenal glands. Following
the remarkable observation in 1998 that a serum shock can
trigger persistent rhythmicity in cultured fibroblasts (50), a
numberof peripheral organs studied ex vivohave been found
capable of maintaining self-sustained oscillations with a
period approximating 24 hours, the main feature defining a
circadian clock (51–53). Thus, as illustrated in Figure 2, the
circadian clock in the SCN is not driving all peripheral
rhythms, but rather acts as a master pacemaker for a mul-
tioscillatory circadian system (54, 55).
B. Molecular mechanisms
At the molecular level, central and peripheral circadian
clocks are based on autoregulatory feedback loops involving
so-called “canonical clock genes” and their protein products
that mutually interact over a 24-hour cycle (Figure 4).
The basic helix-loop-helix transcription factors circadian
Figure 2.
Figure 2. Illustration of the mammalian circadian system as conceptualized circa 2010. The molecular mechanism generating a self-sustained
circadian oscillation in SCN neurons is a complex transcriptional-translational feedback loop comprising core transcriptional activators BMAL1/
CLOCK and two sets of repressors PER and CRY. The core transcriptional activators BMAL1/CLOCK regulate numerous genes, referred to as
“clock-controlled genes” (CCGs).The same molecular machinery has been found in other central tissues as well as in nearly all peripheral tissues
examined so far. The light-dark cycle is the main external synchronizer of the central circadian pacemaker (via the retino-hypothalamic tract
[RHT]), but other external stimuli can affect the phase and amplitude of peripheral oscillators. In particular, the timing of food intake has been
recognized as an important external synchronizer for circadian time-keeping in peripheral organs involved in the control of energy metabolism.
The master clock in the SCN serves to synchronize central and peripheral oscillators to optimize the function of the organism relative to the
24-hour periodicities in the environment. Signals from peripheral tissues can affect the phase and amplitude of the central pacemaker. [Elements
of this figure were published in M. Garaulet and J. A. Madrid: Chronobiological aspects of nutrition, metabolic syndrome and obesity. Adv Drug
Deliv Rev. 2010;62(9–10):967–978 (20), with permission. © Elsevier.]
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locomotor output cycles kaput (CLOCK; or its analog,
neuronal PAS domain protein 2 [NPAS2]) and brain and
muscle aryl hydrocarbon receptor nuclear translocator-like 1
(BMAL1) heterodimerize and initiate the main positive loop
by activation of other clock genes, including three Period
genes (Per 1–3) and two Cryptochrome genes (Cry 1–2).
PER and CRY proteins form complexes that translocate to
the nucleus where they inhibit their own CLOCK/BMALl-
induced transactivation, defining a main negative loop. The
PER/CRY repressor complexes are inactivated by the pro-
teasomal pathway (54, 55). This step is currently thought
to be critical for allowing a new cycle of autoregulation
to restart. CLOCK(NPAS2)/BMAL1 dimers also drive
transcription of nuclear receptors of the reverse viral
erythroblastosis oncogene product (REV-ERB) and
retinoid-related orphan receptor (ROR) families, including
Rev-erb a-b (Nr1d1–2) and Ror a-b-y. In turn, REV-
ERBs and RORs inhibit and activate, respectively, the
rhythmic transcription ofBmal1 andClock (54, 56).Other
genes, such as differentially expressed in chondrocytes 1–2
(Dec 1–2), as well as members of the PAR bZIP tran-
scription factor family define further reinforcing loops
within the molecular clockwork (57–60).
Besides its role as a transcriptional activator, CLOCKalso
has an acetyl-transferase activity driving the cyclic acetylation
of various targets, including histones and BMAL1. Many
other chromatin-modifying enzymes interact with the clock
gene machinery. Among them, the histone deacetylase Sir-
tuin 1 (SIRT1) directly interacts with clock proteins (61).
Post-translational changes, like methylation, phosphoryla-
tion, or ubiquitination, control the stability and cellular lo-
calizationof the clockproteins, thusmodulating theperiodof
the circadian cycle (62).
Many other genes are also transactivated by CLOCK-
(NPAS2)/BMAL1. These clock-controlled genes (Figure 4)
are tissue-specific and generate intra- and intercellular signals
that participate in the translation of temporal information
originating from the clock into physiological functions (54).
Figure 3.
Figure 3. Schematic representation of the pathways involved in the internal synchronization of the central suprachiasmatic (SCN) clock with the
peripheral oscillators in the human circadian system. Both direct neural signals (transmitted by the autonomous nervous system, represented by
black arrows) and indirect hormonal signals are involved. The 24-hour rhythms of circulating melatonin (released by the pineal gland, represented
by a purple circle) and cortisol (released by the adrenals, represented by a blue circle) are considered as primarily controlled by the central SCN
clock. In the schematic representations of the melatonin and GC profiles, the black bars represent the sleep/dark period. The blue and purple
arrows symbolize, respectively, the synchronizing effects of the GC and melatonin rhythms. Because of the ubiquity of GRs in the entire
organism, the 24-hour rhythm of circulating GCs plays a major role in synchronizing central and peripheral clocks. [Modified and redrawn from
P. Pevet and E. Challet: Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris. 2011;105
(4–6):170–182 (99), with permission. © Elsevier.]
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Among these is the gene arginine vasopressin (Avp), for
which rhythmic transcription and translation in SCN
neurons are controlled by the circadian clock (63). The
circadian release of AVP from SCN cells provides
temporal cues to the sub-paraventricular region, a
main target of the master clock (64–66).
C. External synchronizers
Among the environmental factors that impact on
circadian timing, the light-dark cycle and the timing of
food intake are the most powerful synchronizers (often
referred to as zeitgebers, from the German “time giver”),
although, as illustrated in Figure 2, they act at different
levels of the circadian system. The major zeitgeber for the
SCN is ambient light. More precisely, synchronization
with the environmental light-
dark cycle occurs by means of
adjustment of the phase and pe-
riod of the master clock every
day. The term “phase” refers to
the timing of a reference point
(eg, the maximum or the mini-
mum) on a periodic waveform. A
phase shift is an advance or a
delay of the timing of this refer-
ence point. Light-induced phase
shifts depend on the time of the
circadian cycle when light is
perceived. The phase-response
curve to brief light pulses pre-
sented over a background of
constant darkness is character-
ized by phase advances during
the late subjective night (ie, the
end of the active period in noc-
turnal rodents and the end of the
sleep period in humans) and
phase delays during the early
subjective night (67, 68). In
humans, the phase delay region is
generally longer than the phase
advance region, and phase delays
are on average larger than phase
advances. In sum, the “average”
human clock can be more easily
phase delayed than phase ad-
vanced. Light is perceived by
the retinae, which activate the
SCN clock via direct retino-
hypothalamic projections. Im-
portantly, melanopsin, a newly
identified photopigment sensitive
to irradiance (ie, light intensity),
is expressed in a subset of ganglion cells that specifically
project to the SCN (69). These intrinsically photosensitive
ganglion cells are essential for photo-entrainment (70,
71). Yet, the classical cone and rod photoreceptors of the
outer retina, which are vital for the image-forming visual
system, also play an indirect role in transmitting light
conditions to the SCN (72, 73).
Meal timing, when imposed to experimental animals
by temporally restricted feeding to a fairly narrow time
window, is a potent synchronizer for most clocks in pe-
ripheral organs, including the liver, adipose tissue, muscle,
gut, and pancreas. The demonstration that restricted
feeding can uncouple the phase of peripheral clocks from
the SCN, which stays phase-locked to the light-dark cycle
(74, 75), has been a major breakthrough in this field
Box 2. Mineralocorticoid Receptors and Glucocorticoid Receptors
Properties. The MR (nuclear receptor subfamily 3, group C, member 2, NR3C2)
has a 10-fold higher affinity for the naturally occurring GCs (cortisol and corti-
costerone) than the GR (nuclear receptor subfamily 3, group C, member 1,
NR3C1). The MR is not a selective receptor because it can also bind with high
affinity aldosterone and progesterone (35, 36). Aldosterone selectivity in epithelial
cells (kidney, intestine, salivary gland) is conferred by the oxidase 11b-
hydroxycorticosteroid-dehydrogenase type 2 (HSD-2) (37). In the brain, these
aldosterone-selective MRs are restricted to the nucleus tractus solitarius and the
circumventricular organs (38). MR is also expressed abundantly in hippocampal
pyramidal and dentate gyrus neurons, lateral septum, amygdala, and cingulate
neurons (limbic structures), but here the naturally occurring GCs are the principal
ligands because of their 100- to 1000-fold excess over aldosterone (39). Moreover,
neurons express the reductase HSD-1, which regenerates bioactiveGCs. Because of
the 10-fold lower affinity of GRs, these receptors only become occupied when GC
levels are elevated after stress or are near their circadian peak (35). In the brain, the
GR is widely expressed in neurons and glial cells, and most abundantly in typical
stress-regulating centers (eg, PVN of the hypothalamus, limbic structures, fron-
tocortical regions, and ascending aminergic neurons) (40). The GR is nearly
ubiquitous in peripheral tissues, whereas the distribution of the MR is much more
limited. Synthetic GCs (dexamethasone, prednisolone) are ligands for GR.
Molecular mechanisms. MR and GR are ligand-driven transcription factors in-
volved in the regulation of gene expression in interaction with other transcription
factors and coregulators. Recently, both receptor types were also found to rapidly
regulate excitability of neurons. MR increases excitability by enhancing the release
of excitatory transmitters (41–43). GR rapidly promotes the release of endo-
cannabinoids that trans-synaptically attenuate transiently raised excitability (44).
Functions. MR and GR mediate in complementary fashion the action of the
naturally occurring GC.MR operates during the initial phase of the stress response
by facilitating appraisal processes and the selection of an appropriate coping re-
sponse (45–47). Subsequently, with rising GC levels, GR promotes negative
feedback in the HPA axis and behavioral adaptation, while facilitating the storage
of the experience in memory networks for future use (9, 48). When visualized by
functional magnetic resonance imaging, the initial phase of the stress response is
characterized by increased activation of the limbic network (to appraise the most vital
information) at the expense of the frontocortical regions, which later become activated
as part of executive control.MRmanipulationdemonstrates switchingof circuits in the
initial stress reaction, showing the crucial roleof this receptor in the choiceofbehavioral
coping style (49).Onmany (but not all) GC targets (inflammatory, immune, cognition,
emotion),MR andGRmediate opposing actions, suggesting that theMR:GR balance
is crucial for homeostasis/allostasis and adaptation (36).
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because it showed that components of the circadian system
can be synchronized independently of the master SCN
pacemaker. Although the underlying mechanisms are not
totally understood, meal-induced insulin and incretin
hormone secretion could be an important mediator of
entrainment of peripheral clocks by feeding (76–78).
Feeding cues are efficient to adjust the timing of many
circadian clocks and oscillators, not only at the periphery,
but also within the brain of nocturnal rodents (79–82).
Only a few studies have investigated the effects of meal
timing in diurnal (day-active) animals and in humans.
Delaying food access to midnight in diurnal grass rats
shifts their insulin pattern, but not their corticosterone
profile, the latter being only phase-shifted when midnight
feeding is hypocaloric (83). Morning meals rich in car-
bohydrates produce phase advances of circadian rhythms
of body temperature and heart rate in subjects maintained
awake and supine in bed for 48 hours under constant dim
light (84). In contrast, the centrally controlled melatonin
rhythm is not modified. These findings suggest that meal
timing affects human peripheral clocks (84). Daytime
fasting during the month of Ramadan has also been used
to evaluate the effects of temporal restricted feeding in
humans (for review, see Ref. 85). Daily rhythms of plasma
leptin and possibly melatonin display phase delays (86,
87). The impact of Ramadan on plasma cortisol will be
mentioned later (see Section III).
The light-entrainable clock in the SCN is only sensitive
to nutritional cues associated with metabolically chal-
lenging conditions, but not to meal timing per se. For
instance, calorie restrictionmodifies the phase of the SCN
clock and augments the phase shifting effects of light (88).
Moreover, hypercaloric (ie, high-fat) feeding affects the
SCN clock by lengthening its period and reducing its
sensitivity to phase-shifting light exposure (89, 90).
Under normal conditions, the temporal organization
of locomotor activity is controlled by the master clock.
However, enforced locomotor activity during the usual
rest period can have synchronizing effects on the SCN,
thus providing feedback cues to the pacemaker. Behav-
ioral activation in nocturnal rodents, such as novelty-
induced wheel-running, transient hyperactivity, and/or
stimulated arousal during the usual rest period all pro-
duce significant phase advances of the SCN clock
(91–93). In humans, exercise of high intensity at the
beginning of the night (ie, the early rest period) and at the
beginning of the subjective day (ie, early wake time) in-
duces phase delays and phase advances of the onset of
melatonin secretion, respectively, used here as a marker
of the phase of the master clock (94). In contrast to the
SCN, peripheral clocks such as those in the pituitary
gland can also be sensitive to the synchronizing effects of
body temperature cues (95, 96).
D. Internal hormonal and non-hormonal synchronizers
One major route by which the master clock has been
demonstrated to distribute circadian signals to peripheral
clocks is via blood-borne signals (97, 98). Evidence has
accumulated for a key role of two endocrine rhythms tightly
controlled by the master clock: GCs and melatonin.
Rhythmic secretion of adrenal GCs provides temporal
cues to numerous target tissues expressing GR. The role
of the circadian rhythm of circulating GC levels as
internal zeitgeber has been demonstrated for many
Figure 4.
Figure 4. Molecular feedback loops generating circadian rhythmicity
in both central and peripheral tissues. The upper part of the figure
illustrates the interactions with GR activity. The basic transcription
factors CLOCK (or its analog NPAS2) and BMAL1 heterodimerize
and initiate the main positive loop by activation of other clock
genes, including three Period genes (Per 1–3) and two
Cryptochrome (Cry 1–2) genes. PER and CRY proteins form
complexes that translocate to the nucleus where they inhibit their
own CLOCK/BMAL1-induced transactivation, defining a main
negative loop. CLOCK(NPAS2)/BMAL1 dimers also drive transcription
of nuclear receptors of the REV-ERB and ROR families, including
Rev-erb a-b (Nr1d1–2) and Ror a-b-g. In turn, REVERBs and RORs
inhibit and activate, respectively, the rhythmic transcription of Bmal1
and Clock. Although GR activation can reset the phase of the clock
by regulating Per expression and REVERB activity, the clock
machinery modulates GR activity at transcriptional and post-
translational levels in multiple tissues, thus gating the regulation of
GC target genes in a tissue-specific fashion.
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peripheral organs and brain regions. The functional sig-
nificance of this rhythm for the circadian system is the
central theme of this review, and a detailed description of
the experimental evidence is given in Section IV.
Melatonin is synthesized by the pineal gland and se-
creted exclusively at night (in both nocturnal and diurnal
species) under tight control by the master clock via a
multisynaptic pathway. The daily rhythm of plasma
melatonin distributes temporal cues to a multitude of
target tissues expressing melatonin receptors (99). For
example, in the pars tuberalis of the adenopituitary,
rhythmic oscillations of clock genes (ie, Cry1 and Per1)
are under the control of circulating melatonin (100).
Studies on pinealectomized rats indicate that endogenous
melatonin acts as an internal zeitgeber, enhancing syn-
chronywithin the circadian system (101). The presence of
melatonin receptors in the SCN shows that endogenous
melatonin may have feedback effects on the master clock.
During embryonic development, maternal melatonin
provides time cues to the SCN and adrenal glands of the
fetus (102, 103). In adults, pharmacological doses of
melatonin administered in the late (subjective) day pro-
duce phase advances of the master clock in both noc-
turnal and diurnal species, including humans (99).
Another route by which the master clock distributes
circadian signals to peripheral organs is through the
projections of the sympathetic and parasympathetic
branches of the autonomic nervous system. The in-
nervation of the liver has attracted much attention in that
regard (104). In particular, treatment with the sympathetic
neurotransmitter noradrenaline up-regulates transcription
of Per1 mRNA levels in the liver both in vivo and in vitro.
Moreover, electrical stimulation of the sympathetic nerves
or adrenaline injection triggers Perl transcription measured
by bioluminescence in the liver of transgenic Per1-luc mice
(105). Similarly, in the adrenal gland, autonomic innerva-
tion serves as a time signal to adrenal endocrine rhythms
(106, 107). By the same route, light exposure directly ac-
tivates adrenal Per gene expression independently of the
SCN clock (108, 109). Other organs with well-studied
autonomic control by the SCN include the pineal and
sub-maxillary glands (106, 107, 110, 111).
III. The Circadian Rhythmicity of Glucocorticoid
Release
A. Normal circadian and pulsatile variations of
glucocorticoid release
GC secretion is characterized by both circadian and
60- to 90-minute (ie, ultradian) oscillations. As detailed
below, outputs from the SCN activate rhythmic release of
corticotropin-releasing hormone (CRH) that stimulates
circadian release of corticotropin (ACTH). The circadian
rhythm of adrenal GC secretion is primarily dependent
on this circadian pattern of ACTH release. In addition,
neuronal signals generated by the SCN are transmitted
by a multi-synaptic neural pathway to the adrenal cortex
(106). In the adrenal cortex, an intrinsic circadian os-
cillator gates the physiological adrenal response to
ACTH, defining a time window during which the adre-
nals most effectively respond to ACTH (22, 112).
In humans, under normal conditions, the 24-hour
profiles of ACTH and cortisol show an early morning
maximum, declining levels throughout daytime, a
quiescent period of minimal secretory activity usually
centered around midnight, and an abrupt elevation
during late sleep culminating in an early morning
maximum (113). An example of simultaneous profiles
of ACTH and cortisol in a healthy young man studied
under normal conditions is shown in Figure 5. In
nocturnal rodents, the levels of corticosterone peak
around the light-dark transition when the animals
become active (107).
Around the time of the nadir of HPA axis activity,
concentrations of ACTH and cortisol in humans can
be near the limit of detection of routinely used assays.
Morning maxima of cortisol concentrations are often
Figure 5.
Figure 5. Representative 24-hour profiles of plasma ACTH and
cortisol levels sampled at 15-minute intervals in a healthy young
man studied under normal conditions. During scheduled sleep times
(shown as a black bar), the sampling catheter was connected to
plastic tubing extending into the adjacent room to avoid disturbing
the subject. The parallelism of both pulsatile and circadian variations
of ACTH and cortisol concentrations is evident.
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within the range of pathological values for afternoon and
evening levels. Overall, the amplitude of the circadian
variation of plasma cortisol is among the largest that can
be detected in the human endocrine system (114). There is
substantial evidence from studies in nocturnal rodents
that the amplitude of the ACTH rhythm is considerably
lower than that of the corticosterone rhythm, indicating
that mechanisms downstream of pituitary control en-
hance the circadian variation of GC production. In
humans, as evident in the example shown in Figure 5, the
amplitude of the ACTH rhythm is more similar to that of
the cortisol rhythm. Under normal conditions, the
acrophase of pituitary-adrenal periodicity occurs be-
tween 6 and 10 AM and the nadir between 10 PM and 2 AM.
Mathematical derivations of secretory rates from plasma
concentrations have suggested that the 24-hour profile of
plasma cortisol reflects a succession of secretory pulses of
magnitude modulated by a circadian rhythm with no
evidence of tonic secretion (114). With a 15-minute
sampling interval, 12 to 18 significant pulses of plasma
ACTH and cortisol per 24-hour span can be detected
(115). Circadian and pulsatile variations parallel to that
of cortisol have been demonstrated for the plasma levels
of several other adrenal steroids, in particular, dehydro-
epiandrosterone (116, 117). Circadian variations in GC
release can also be detected in urine and feces with phase
delays compared to blood (118–120). As illustrated in
Figure 6, levels of free cortisol can be reliably measured in
saliva and are highly correlated with circulating con-
centrations of total cortisol under normal condi-
tions (117).
B. Control of the circadian variation of glucocorticoid
levels
Circadian variations in GC release are governed by a
complex interaction of central and peripheral clocks in
the SCN, the PVN of the hypothalamus, the pituitary
corticotrophs, and the adrenocortical cells producing
steroids (121). Figure 7 provides a schematic represen-
tation. The pivotal role of the SCN in the circadian
control of GC release was recognized in 1979, when
destruction of the SCN in rats was shown to eliminate the
rhythms of ACTH and corticosterone (122). The importance
of neural connections with other hypothalamic regions was
recognized when SCN grafts in animals with complete ab-
lation of the SCNwas found to restore rhythms of locomotor
activity, but not of circulating corticosterone (123).
Control by the master clock in the SCN is mediated via
two pathways, a neuroendocrine path (ie, the HPA axis)
and a nervous path (ie, the sympathetic system) (31, 107).
In rats, SCN pacemaker neurons rhythmically release
the neuropeptide vasopressin (124), which inhibits CRH
neurons in the PVN, the structure that constitutes the top
of theHPA axis. The fact that the SCN control of theHPA
axis rhythm involves inhibitory mechanisms was first
suggested by the fact that SCN lesions resulted in corti-
costerone increases at the time of the trough of the
rhythm. Vasopressin release from the SCN is high during
the light phase, and interestingly, PVN neurons of diurnal
species as compared to nocturnal species respond dif-
ferently to vasopressin stimulation (107, 125). This
control of CRH activity in the PVN may occur via va-
sopressin release into the cerebrospinal fluid or extra-
cellular space (64), via direct projections from the SCN to
the PVN (126), or via indirect projections to sub-
paraventricular GABAergic interneurons that in turn
project to the PVN (125). It is likely that vasopressin is
not the only SCN signal controlling the daily cortico-
sterone rhythm. Overall, the rhythm seems to be con-
trolled by a balance between inhibitory and stimulatory
inputs from the SCN (107). The clockwork machinery is
present in the PVN and has been shown to generate self-
sustained oscillations of Per1 expression when isolated
in vitro (127).
Although experimental evidence is scarce, the PVN
clock might be involved in the 24-hour variation of CRH
mRNA levels that peaks at night in rats (128, 129). The
Figure 6.
Figure 6. Simultaneous profiles of plasma total cortisol (solid line)
and saliva free cortisol (dashed line) in two healthy young adults
who were each submitted to blood sampling via an indwelling
catheter at 20-minute intervals from 9 AM to midnight and provided
a saliva sample at the time of each blood sampling. Caloric intake
was exclusively in the form of a glucose infusion at a constant rate
of 5 g/kg/24 h. Simultaneous levels of plasma cortisol and saliva
cortisol were highly correlated in both individuals (r: Pearson
correlation coefficient). [Unpublished illustration of data included in
A. Guyon et al: Adverse effects of two nights of sleep restriction on
the hypothalamic-pituitary-adrenal axis in healthy men. J Clin
Endocrinol Metab. 2014;99(8):2861–2868 (117), with permission. ©
The Endocrine Society.]
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negative feedback of GCs controls the release of pituitary
ACTH, with higher sensitivity during the nadir (trough)
of the 24-hour rhythm. A role for vasopressin release
from the PVN in the control of rhythmic ACTH release
has been suggested by human experiments where nega-
tive feedback regulation by GCs was eliminated by
metyrapone treatment and CRH was infused iv at a
constant rate. Under these conditions, a clear 24-hour
rhythm of ACTHwas observed, but it was set at a higher
mean level due to the absence of negative feedback (130).
High-affinity MRs in limbic structures, such as the hip-
pocampus, mediate the effect of GCs on the maintenance
of basal activity in the HPA axis at that nadir time (late
evening in humans, early morning in nocturnal rodents).
The more abundant GRs in the hippocampus are thought
to play an important role when the HPA axis is activated
(at the time of the circadian peak and during stress re-
sponses; see Box 2) (131). More recently, theMR, bound
to the plasma membrane, has been shown to be involved
in the initial steps of the response to psychological stress
(132) (see Box 1).
After secretion of CRH in the portal system of the
median eminence, ACTH synthesized in the anterior
pituitary is released into the circulation and stimulates
GC secretion from the adrenal cortex. In rats, Pomc
mRNA levels in the anterior pituitary do not show
Figure 7.
Figure 7. Schematic representation of the control of the circadian rhythmicity of GC release in mammals. Most components of the HPA axis
contain circadian oscillators. The circadian secretion of GC is dependent on the rhythmic release of ACTH and a gating process by the adrenal
clock. GC secretion is also modulated by nervous signals coming from the PVN of the hypothalamus via sympathetic nervous pathways. ACTH
release is controlled by the rhythmic release of CRH and vasopressin from the PVN. Rhythmic activity of the HPA axis is under the control of the
master clock in the SCN, reset by ambient light via the retina. The peak of vasopressin release from the SCN to the PVN region occurs during
daytime in both nocturnal and diurnal rodents. In nocturnal rats, vasopressin exerts an inhibitory action on the PVN (probably via activation of
g-aminobutyric acid-containing interneurons), thus reducing GC secretion during daytime (green curve). By contrast, in diurnal grass rats,
vasopressin stimulates PVN activity (probably via activation of glutamatergic interneurons), thus increasing GC secretion during daytime (red
curve). Clock symbols represent self-sustained oscillators.
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significant 24-hour rhythms despite the fact that clock
genes appear to be expressed and to oscillate in anterior
pituitaries from both rodents and humans (52, 129, 133,
134). Therefore, Pomc transcription is probably not a
clock-controlled process in the pituitary. Plasma ACTH
levels in rats are higher in the evening compared to
morning, and this dusk increase in ACTH is dampened by
SCN lesions (135, 136). Further findings indicate that
the SCN increases adrenal sensitivity to ACTH, espe-
cially during the rising portion of the 24-hour rhythm of
corticosteroids. This modulation of the sensitivity of
the adrenal glands to the incoming ACTH message is
partly mediated through autonomic pathways (106,
137, 138). More precisely, SCN and other signals in-
tegrated in the PVN are transmitted to neurons in the
intermediolateral column of the spinal cord, which then
project via splanchnic fibers directly to the adrenal
glands (106, 138).
Although little is known about circadian modulation
at the level of the PVN or the pituitary, work with
transgenic mice suggests that local clocks in adrenocor-
tical cells gate the sensitivity of the adrenal steroidogenic
pathway to ACTH stimulation (22, 139, 140). Adrenal
slice cultures from wild-type animals show different
responses to ACTH stimulation depending on the time
of treatment (22, 141). Adrenal slices from animals
with genetically disrupted clock function lack this capa-
bility (22). Furthermore, adrenal function and responses to
both acute and chronic stress are altered in mice with
defective circadian clocks due to genetic ablation ofBmal1
(142). Together, these data suggest that a stable phase-
relationship between central (SCN) and peripheral
(adrenocortical) clocks is necessary to maintain robust
high-amplitude circadian rhythms of GC release (143).
C. The 24-hour profile of glucocorticoid secretion is a
robust marker of the central circadian signal
Consistent with its role as the main hormonal signal
synchronizing the master circadian pacemaker with a
multitude of peripheral clocks, the 24-hour cortisol
profile is relatively unaffected by acute changes in envi-
ronmental and behavioral conditions.
The mean profile of cortisol levels shown in Figure 8
illustrates the persistence of the cortisol rhythm after an
acute shift of the light-dark cycle and sleep-wake cycle
and in the absence of alternations between feeding and
fasting. Eight normal young men were studied during a
53-hour period that included 8 hours of nocturnal sleep
in total darkness, 28 hours of continuous wakefulness
in a semirecumbent position with constant indoor light
exposure, and 8 hours of daytime sleep (144). Caloric
intake was replaced by an iv glucose infusion at a con-
stant rate. It can be seen that the overall wave shape of the
profile was only modestly affected by the absence of sleep
or the presence of sleep at an abnormal time of day.
During the 28 hours of constant recumbent posture,
continuous wakefulness, constant exposure to indoor
light, and constant caloric intake, the normal wave shape
of the rhythm of GC release was clearly maintained.
Similar findings have been obtained in multiple labora-
tories (145).
Adaptation of the 24-hour rhythm of cortisol to an
abrupt phase shift of dark-light cycle, sleep-wake cycle,
and feeding schedule, as occurs in jet lag and in certain
types of shift work rotation, requires multiple days,
usually 1 day per time zone in the case of jet lag.When the
change in sleep-wake and dark-light cycle occurs grad-
ually, the shift in the cortisol rhythm correlates with the
shift in the rhythms of other processes known to be under
central circadian control, including melatonin release,
body temperature, and subjective alertness (32). An
abundance of similar evidence linking the characteristics
of outputs from the master clock with the rhythm of
cortisol release has led to the widespread use of the
24-hour rhythm of plasma cortisol in humans and of
corticosterone in rodents as a marker of central circadian
timing.
However, the overt rhythm of GC release can be af-
fected bymultiple stimuli that evoke transient stimulatory
Figure 8.
Figure 8. Mean profiles of plasma cortisol concentrations measured
at 20-minute intervals from eight healthy young men studied over
a 53-hour period including a night of nocturnal sleep (black bar),
28 hours of continuous wakefulness in a semirecumbent position
with a night of total sleep deprivation (red bar), and an 8-hour
period of daytime recovery sleep (blue bar). Caloric intake was
exclusively in the form of an iv glucose infusion at a constant rate.
The persistence of the circadian rhythmicity of plasma cortisol
despite these drastic manipulations of the light-dark cycle, sleep-
wake cycle, and feeding schedule is evident. Note that the absence
of wake-sleep and sleep-wake transitions during the night of total
sleep deprivation results in a slight dampening of the amplitude of
the circadian variation. [Redrawn from E. Van Cauter et al:
Modulation of glucose regulation and insulin secretion by circadian
rhythmicity and sleep. J Clin Invest. 1991;88(3):934–942 (144), with
permission. © American Society for Clinical Investigation.]
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or inhibitory responses. For example, modulatory effects
of sleep-wake transitions are well recognized and are
discussed in Section V. Feeding and fasting have potent
effects on GC secretion and can therefore also affect the
shape of the 24-hour profile of GC levels. In humans,
under normal conditions, a short-term elevation of cor-
tisol levels occurs reliably after ingestion of a carbohy-
draterich meal presented at 12- or 6-hour intervals
(Figure 9). The detection of this meal response requires a
strict standardization of the timing and composition of
the meal for a group of subjects in order to be differ-
entiated from spontaneous pulsatile release. The profiles
shown in Figure 9 indicate that these evoked meal re-
sponses do not affect the overall amplitude and phase of
the circadian rhythm of cortisol release (146). Of note, in
this study, the duration of fasting between meals was not
long enough to cause a reduction of glucose levels
approaching the hypoglycemic threshold that might have
triggered a counter-regulatory increase in cortisol release.
The first line of glucose counter-regulation is activated
around 3.75 mmol/L (68 mg/dL) and involves increased
release of glucagon, adrenaline, and GH (147). An in-
crease in cortisol does not occur until glucose levels are
below 3.5 mmol/L (63 mg/dL). In nocturnal rodents (in
which intermeal fasting periods are habitually short), a
nutritional challenge consisting of restricting daily food
access to a few daytime hours (ie, during their resting
period) results in the appearance of a food-anticipatory
rise in circulating corticosterone before the mealtime, in
addition to the nocturnal rise controlled by the master
clock. The additional daytime peak is ACTH independent
(148, 149) and has been associated with noradrenergic
activation of the PVN (150). Concomitant with the an-
ticipatory rise in corticosterone before mealtime, animals
manifest bouts of motor activity and thermogenesis
driven by a network of cerebral clocks outside the SCN
(151). In humans, daily profiles of plasma cortisol have
been studied during the traditional Muslim Ramadan, a
1-month period when caloric intake and water intake are
restricted to the nighttime. In addition to the morning rise
of plasma cortisol, a secondary increase in cortisol was
observed in the late afternoon, before the expected time
for eating (87, 152). These studies are limited by in-
frequent blood sampling at 4-hour intervals or longer,
and because glucose levels were not measured, it remains
unclearwhether the 18-hour fast elicited counter-regulatory
cortisol release.
Environmental lighting conditions matter not only
for resetting the master clock, but also for modulating
adrenal activity. In mice, light exposure at night triggers
corticosterone release via sympathetic pathways with-
out inducing ACTH release (108). Conflicting results
have been obtained in rats in which light exposure at
night leads to a decrease in blood corticosterone (106).
Nevertheless, in both studies, the effect of light appears
to be ACTH-independent and mediated by sympathetic
inputs originating from the PVN. In humans, bright
light in the early morning, but not in the afternoon,
induces a robust transient elevation of plasma cortisol,
highlighting the strong modulatory effect of light
conditions on the rhythmicity of the human HPA
axis (153).
Figure 9.
Figure 9. Mean profiles of plasma cortisol concentrations measured at 20-minute intervals from eight healthy young men who each participated
in a randomized clinical trial comparing the impact of either two or three identical carbohydrate-rich meals presented at fixed clock times. A clear
short-term increase in cortisol concentrations occurs after each meal but does not affect the overall wave shape of the circadian profile. Thus,
acute changes in feeding schedules that have a major effect on peripheral circadian oscillators in metabolic tissues do not readily desynchronize
the GC rhythm from the central circadian pacemaker, consistent with its role as a robust internal synchronizing signal. [Adapted from E. Van
Cauter et al: Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. Am J Physiol. 1992;262(4 Pt 1):
E467–E475 (146), with permission. © American Physiological Society.]
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In rodents, chronic exercise increases the daily peak of
plasma corticosterone. This occurs mainly by an in-
creased synthesis of corticosteroid in the adrenals (154,
155). In humans, acute voluntary exercise also produces a
transient stimulation of cortisol secretion (156, 157).
Exposure to stressors can acutely increase ACTH and
GC release, but the response is generally superimposed on
the 24-hour endogenous rhythm, without intrinsic effect
on either phase or amplitude. The HPA axis shows daily
variations in its responsiveness to acute exposure to
various stressors. In conscious rats, corticosterone in-
duction as a marker of HPA reactivity in response to
noise, restraint stress, and ACTH administration is larger
in the early light phase when spontaneous corticosterone
activity is low compared to the early dark phase when
spontaneous activity is high (136, 137, 158). The HPA
response to insulin-induced hypoglycemia is also time-of-
day dependent, but with opposite direction compared to
psychological stressors (eg, restraint) (159). However, in
chronically stressed humans, cortisol levels are often el-
evated throughout the day, thus blunting the normal day-
night variation (160, 161). Well-documented examples
include major depressive disorder (162–164) and chronic
insomnia (165).
D. Contrasting diurnal and nocturnal species
The 24-hour rhythm of corticosteroids is oppositely
phased between diurnal and nocturnal mammals with
respect to the light-dark cycle (ie, dawn and dusk, re-
spectively; see Figure 7), but it anticipates the onset of the
daily period of wakefulness and activity in both groups
(158, 166), participating in the mobilization of energy
stores and the stimulation of appetite (167).
In contrast, molecular oscillations of the master clock
and its outputs (eg, vasopressin) are phase-locked with
respect to the light-dark cycle in both day- and night-
active species (63, 168, 169). Together, these data suggest
that the functional switch between diurnal and nocturnal
behaviors occurs downstream of the SCN (probably in
the first-order targets of SCN output signals) (170). In
keeping with that hypothesis, intracerebral injections of
vasopressin have opposite effects on HPA axis activity
between nocturnal laboratory rats and diurnal Sudanian
grass rats, with respectively inhibitory and stimulatory
actions on corticosterone release (125) (see Figure 7).
These findings suggest that the neurochemical nature of
the subparaventricular interneurons mediating these ef-
fects (ie, GABAergic or glutamatergic, respectively) may
participate to the diurnal vs nocturnal niche of the animal.
The opposite phasing of GC rhythms and sleep-wake
cycles relative to SCN neuronal activity, melatonin re-
lease, and the light-dark cycle between diurnal and
nocturnal species has raised concerns about the suitability
of nocturnal rodents as model systems for developing
drugs that target the human HPA axis and metabolism.
Further studies in diurnal mammalian species, such as
Sudanian grass rats, dogs, or rhesus monkeys, may thus
provide important insights into the clinical significance
and pathophysiological mechanisms underlying condi-
tions of abnormal GC rhythmicity and help in the design
of therapeutical approaches.
E. Control and functional significance of
glucocorticoid pulsatility
In every mammal studied so far, GCs are released in a
pulsatile fashion with large amplitude pulses during the
active awake period and infrequent low amplitude pulses
during the early hours of sleep. This pulsatile activity
emerges as a natural consequence of the feed-forward
feedback relationship between the anterior pituitary
corticotrophs and the zona fasciculata of the adrenal
cortex (171). Indeed, infusion of constant levels of CRH
during the nadir of HPA activity is sufficient to result in
pulsatile ACTH and corticosterone secretion (172),
whereas blocking the activity of the SCN abolishes cir-
cadian rhythmicity but allows ultradian rhythmicity to
continue throughout the 24 hours (173).
Pulsatile ACTH and GC secretion results in an os-
cillating signal of hormone ligand, and therefore it is
likely that the receptor signaling pathways have adapted
to decode this oscillatory signal. This appears to be the
case both for the adrenal cortex, which preferentially
responds to pulsatile signals of ACTH, and for other
tissues expressing GR around the body (174, 175). Be-
cause GCs secreted by the adrenal cortex are synthesized
de novo, the pulsatile activity of this gland must be the
result of a very dynamic and tightly controlled process.
Recent evidence suggests that this activity is regulated via a
fine balance between ACTH-mediated feedforward and
GC-mediated intra-adrenal feedback (176). These path-
ways are activated by protein kinase A-mediated genomic
and nongenomicmechanisms (177). Interestingly, in critical
illness, although pulsatility is maintained, there appears
to be a change in intra-adrenal signaling, resulting in a
markedly increased sensitivity to circulating ACTH (178).
We now know that there is a differential response of
many genes to constant vs pulsatile administration of
GCs (179), and in vivo studies have confirmed that each
individual pulse of GC is associated with cyclical binding
of the GR and coregulatory molecules to promoter se-
quences of GC response genes and cyclical activation of
transcription (180). Recent evidence suggests that the
differential responses to different temporal patterns of
GC ligand depend on spatiotemporal chromatin dy-
namics reflecting transient activation of distal regulatory
elements (181).
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The differential effects of pulsatile vs constant GC are
not only seen at the molecular level. When corticosterone
replacement is given to adrenalectomized rats, animals
given pulsatile replacement therapy have a normal neu-
roendocrine and behavioral response to a 10-minute
noise stress, whereas animals given exactly the same dose
of GC, but as a constant infusion, have dulled responses
(182). Interestingly, these animals also show a stress-
induced neuronal activation in the amygdala that is de-
pendent upon the pulsatility of the infused corticosterone
(182). Recent work reveals that the ultradian pulsatile
pattern plays an important role for normal glutamatergic
synaptic transmission (183).
These animal studies clearly show that for normal
transcriptional and behavioral responses, it is necessary
that GCs are presented to their target tissue in a pulsatile
fashion rather than in a smooth pattern. The question
arises, of course, as to how important this may be in
humans. To date, there have been relatively few studies of
the importance of cortisol pulsatility in human patho-
physiology, although there is evidence for altered pulse
dynamics in depression (184) and in obstructive sleep
apnea (185).
IV. Impact of the 24-Hour Rhythm of
Glucocorticoid Levels on Central and
Peripheral Oscillators
The 24-hour rhythm of adrenal corticosteroids provides
temporal cues to circadian clocks and physiological
rhythms in numerous central and peripheral tissues
expressing GR. Conversely, disturbances of the physio-
logical rhythm of GCs by chronic continuous adminis-
tration of synthetic corticosteroids such as prednisolone
or by adrenalectomy have been experimentally shown to
markedly alter circadian oscillations of clock gene ex-
pression in multiple tissues (186). It is important to note
that negative findings regarding the impact of adrenal-
ectomy (a condition where GC concentrations are at
nadir levels throughout the 24-hour cycle) on a given
clock system do not exclude the possibility that an acute
elevation of GC concentrations at the normal nadir time
in an adrenalectomized animal will not disrupt rhythmic
clock expression in target tissues. Multiple studies have
obtained evidence for a role of GC in synchronizing local
clocks by demonstrating altered rates of re-entrainment
in adrenalectomized animals (187).
A. Synchronization of non-SCN brain clocks and rhythms
Table 1 lists the central nervous system regions for
which there is evidence of rhythmic expression of clock
genes as well as expression of GR, and it summarizes the
evidence for a potential implication of GCs in regulating
local oscillators and rhythms. All the findings derive from
rodent studies.
1. Suprachiasmatic nuclei
The master SCN clock does not express sizeable
amounts of GR, except during the first postnatal week in
rats (188). Adrenalectomy has no major effect on rhythms
Table 1. Evidence for GR Regulation of Local Circadian Clocks and Rhythms in Brain Tissues
Tissue
Evidence for
Presence of
Local Clocks
Expression
of GRs
Do GCs Impact
Local Clocks or
Rhythms?
Potential Functional
Significance of Local
Clock and Impact of GC
Selected Refs.
Investigating the
Impact of GCs on
Cellular Rhythms
SCN Yes No No Robustness of the master circadian
signal relative to disturbances of GC
levels or rhythmicity
200
Pineal Yes No No Robustness of the other hormonal
internal zeitgeber relative to
disturbances of GC levels or
rhythmicity
205
PVN Yes Yes Yes Modulation of stress response and
sympathetic tone
189, 192
Arcuate nucleus Yes Yes Unknown Modulation of hunger, appetite, and
feeding
N/A
Central amygdala Yes Yes Yes Modulation of emotion 196
Bed nucleus of stria
terminalis
Yes Yes Yes Modulation of reward, anxiety, and
stress
196
Raphe nucleus No Yes Yes Modulation of feeding, arousal, mood,
sleep, cognition, and master clock
199
Hippocampus Yes Yes Yes Modulation of stress, emotion,
memory, neurogenesis, response to
antidepressant treatment
197, 198
Abbreviation: N/A, not available.
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of circadian gene expression in the SCN (189). GCs may,
however, influence the central circadian signal in an indirect
fashion via behavioral modulation, for example, during re-
entrainment of activity rhythms after jet lag (190).
2. Paraventricular nucleus
Adrenalectomy in rats reduces the amplitude of the
daily expression of Per1, suggesting that the daily rhythm
in corticosterone modulates robustness of the circadian
rhythmicity in the PVN (189). Furthermore, acute stress
induces expression of the clock gene Per1 in the PVN
(191, 192).
3. Arcuate nucleus
The arcuate region displays self-sustained in vitro
oscillations, as assessedwith PER2::LUCmice (193), and
GRs are expressed in this area (194, 195). To our
knowledge, the possible effect of GCs on the arcuate
clock has not yet been investigated.
4. Limbic areas
Several limbic regions (eg, central amygdala and bed
nucleus of the stria terminalis) show daily oscillations
of clock proteins that are suppressed by adrenalectomy.
In these adrenalectomized animals, rhythmic expres-
sion of the clock protein PER2 can be restored by
exposure to a daily rhythm of corticosterone levels
obtained by exogenous administration in the drinking
water (196). Expression of the clock gene Per1 in the
hippocampus is also modulated by circulating GCs
(197, 198).
5. Raphe
GC-mediated resetting of physiological rhythms has
also been observed in the raphe nuclei, although this
brain region does not express clock genes. In this brain
region, circulating corticosterone levels indeed control
the rhythmic transcription of tryptophan-hydroxylase,
the ratelimiting enzyme of serotonin synthesis (199).
In summary, there is substantial evidence that the
24-hour rhythm of plasma GCs normally generated by
the adrenal glands participates in the adaptation of daily
rhythmicity in multiple brain tissues.
B. Synchronization of peripheral clocks and rhythms
As listed in Table 2, rhythmic expression of circa-
dian genes has been detected in a wide variety of pe-
ripheral tissues that also express GR. Furthermore, in
Table 2. Evidence for GR Regulation of Local Circadian Clocks and Rhythms in Peripheral Tissues
Tissue
Evidence for
Presence of
Local Clocks
Expression
of GRs
Do GCs Impact
Local Clocks
or Rhythms ?
Potential Functional
Significance of Local
Clock and Impact of GC
Selected Refs.
Investigating
the Impact of
GCs on Cellular
Rhythms
Liver Yes Yes Yes Modulation of gluconeogenesis,
lipid metabolism
200, 203
Muscle Yes Yes Yes Modulation of muscle atrophy,
sarcopenia
186, 207
Pancreatic b-cells Yes Yes Unknown Modulation of glucose tolerance,
diabetes risk
N/A
White adipose tissue Yes Yes Yes Modulation of lipid metabolism,
appetite regulation,
inflammation
189, 211
Gut Yes Yes Unknown Altered intestinal lipid absorption N/A
Heart Yes Yes Yes Modulation of atrioventricular
transmission
200
Kidney Yes Yes Yes Modulation of filtration, volume
regulation
200, 205
Lung Yes Yes Yes Modulation of immune function 218, 219
Skin Yes Yes Yes Modulation of immune function,
hair cycle
200, 221
Ovary Yes Yes Yes Modulation of steroidogenesis,
follicle survival
222
Blood (mononuclear cells) Yes Yes Yes Immune function 219, 226, 227
Salivary gland Yes Yes Yes Unknown 205
Bone Yes Yes Yes Modulation of osteoclast survival,
bone resorption
230
Cornea Yes Yes Yes Modulation of local immune
function, lymphangiogenesis
205
Pituitary gland Yes Yes Yes Unknown 205
Abbreviation: N/A, not available. Except where indicated in the main body of the text, the findings derive from rodent studies.
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almost all of the tissues examined so far, an impact of
modulation of GC levels and/or rhythmicity on the pe-
ripheral clock has been demonstrated. Except where in-
dicated below, the findings derive from rodent studies.
1. Liver
Treatment with dexamethasone, a potent synthetic
GC, is a potent synchronizer of the liver clock in mice,
with the direction and amplitude of the phase
depending on the timing of treatment (200, 201).
In vitro treatment with prednisolone also affects clock
gene expression in cultured hepatocytes, whereas
continuous administration of this synthetic GC in
mice attenuates the daily oscillations of clock genes in
the liver (186). Lesions of the SCN lead to arrhyth-
micity of the liver transcriptome, whereas a single
injection with dexamethasone restores daily rhythms
in hepatic gene expression (202). Adrenalectomy in
mice affects the circadian expression of metabolic
genes, such as glucokinase or 3-hydroxy-3-methyl-
glutaryl-coenzymeA reductase, but not that of clock
genes (203, 204). However, in vitro circadian oscil-
lations of livers sampled from adrenalectomized rats
are delayed compared to sham-operated control an-
imals (205). Chronic mild stress disturbs daily pat-
terns of hepatic expression in metabolic and clock
genes (206).
2. Kidney
Dexamethasone or corticosterone shifts clock gene ex-
pression in that tissue (200, 201), whereas adrenalectomy
delays the phase of ex vivo Per1 oscillations (205).
3. Skeletal muscle
Circadian expression of genes in rat skeletal muscles
can be modulated by corticosterone (207), whereas
continuous treatment with prednisolone diminishes the
daily amplitude of clock gene expression in the mouse
muscle (186).
4. Pancreatic b-cells
Marcheva et al (208) demonstrated the existence of
robust autonomous circadian oscillations of Per2, as-
sociated with rhythmic expression of genes involved in
insulin signaling, glucose uptake and metabolism, and
b-cell growth and proliferation. Animals in which the
circadian clock in the pancreas has been genetically
manipulated have defects of insulin release and abnormal
glucose homeostasis (208, 209). In healthy humans under
conditions of constant glucose infusion, insulin secretion
rates show a circadian variation that is inversely related
to the cortisol rhythm,with a significant correlation in the
amplitudes of the two rhythms (144).
5. White adipose tissue
Dexamethasone increases and attenuates the ampli-
tude of clock gene oscillations in preadipocytes and
differentiated adipocytes, respectively (210). Further-
more, adrenalectomy in rats suppresses oscillations of
metabolic genes, such as leptin, adiponectin, or peroxi-
some proliferator-activated receptor a, and diminishes
the amplitude of clock gene oscillations, including Per1
and Rev-erb a (189). In human adipose explants,
dexamethasone treatment alters clock gene expres-
sion (211).
6. Gut
The expression of various clock genes has been
documented in parts of the intestine (212). The colon
exhibits the highest expression of clock genes (213,
214). The expression of clock genes increases from
duodenum to colon and from mucosal cells to epithelial
cells. Clock genes in the jejunum and colon show cir-
cadian variations (212–214) that are in phase with their
rhythmic expression in the liver but are phase delayed
compared to their temporal expression in the SCN (75).
It has recently been shown in mice that the intestinal
microbiota exhibit endogenous circadian rhythmicity
that is partly synchronized by host feeding and de-
pendent on diet composition (215–217). Reciprocally,
circadian variations of gut microbes affect rhythms of
clock gene expression in the mediobasal hypothalamus
and in the liver. High-fat diet markedly alters circadian
patterns of gut microbial structure and function,
resulting in the disruption of both central and liver
clocks with adverse metabolic consequences. It is not
known whether circadian variation in GCs may play a
role in the interactions between rhythms in the micro-
biota and rhythms in the host.
7. Lung
The epithelial cells of the lung express clock genes that
are sensitive to activation of GC signaling (218). Daily
injections of corticosterone modify expression patterns of
clock genes in the rat lung (201), whereas the disap-
pearance of rhythmic GCs is without detectable effects on
the phase of Per1 oscillations (205). In human bronchial
epithelial cells, dexamethasone leads to an increased
expression of the clock gene Per1 (219).
8. Heart
Dexamethasone is able to shift clock gene expression
in the cardiac muscle (200, 220).
9. Pituitary
Adrenalectomy hardly affects the daily expression
patterns of clock genes in the hypophysis (133, 205) and
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does not affect the rate of re-entrainment after a delay or
advance of the light-dark cycle (205). However, hydro-
cortisone treatment of adrenalectomized animals ad-
vanced the rhythm of Per1-luc expression.
10. Salivary gland
There is no evidence for a role of the GC rhythm in
synchronizing the clock in the salivary gland (205), in-
dicating that other internal pathways are more important.
11. Cornea
In rats, adrenalectomy delays Per1-luc oscillation of
the cornea, this phase shift being partially counteracted
by hydrocortisone treatment (205).
12. Skin
Dexamethasone triggers expression of clock genes in
cultured rat-1 fibroblasts (200). Clock gene oscillations in
primary fibroblasts, keratinocytes, andmelanocytes from
human skin explants can also be phase-adjusted by dexa-
methasone (221).
13. Ovary
Cultured granulosa cells from ovaries of Per2-luc rats
can be synchronized by dexamethasone treatment (222).
14. Blood mononuclear cells
Clock genes are rhythmically expressed in blood nu-
cleated cells (223, 224), whereas GR acetylation in these
cells shows day-night variations (225). Timed treatment
with GCs synchronizes the local clock in these cells in
in vitro and in vivo conditions (226, 227).
15. Bone
Metabolism of bone is modulated by clock genes
(228). In turn, the bone clock in humans and mice can be
reset by dexamethasone (229, 230).
C. Impact on photic entrainment
It is worth mentioning that GCs can also modulate the
entrainment of the SCN pacemaker to light. Notably,
when animals are exposed to an abrupt shift in the
light-dark cycle (jet-lag paradigm), blocking the synthesis
of adrenal corticosteroids or submitting the animal to
adrenalectomy changes the speed of re-entrainment of the
circadian system to the new light-dark schedule (187,
190, 205). As mentioned earlier, the fact that GR are not
found in the adult SCN suggests that these effects are
mediated indirectly.
D. Impact on entrainment by food intake
When combined with timed meal access, GC signaling
can provide conflicting resetting cues, thus impairing
entrainment of peripheral organs (204, 231). This mod-
ulatory effect may be tissue-dependent because the liver
clock appears to be more sensitive to feeding cues,
whereas the lung and kidney are more easily reset by
corticosteroids (201).
E. Reciprocal interaction: clock proteins modulate
glucocorticoid receptor activity and bioavailability
Although there is ample evidence that GC rhythmicity
provides synchronizing cues to a number of central and
peripheral clocks (Tables 1 and 2), conversely, in a
number of peripheral tissues including liver, white and
brown adipose tissue, bone, prefrontal cortex, and aorta
(232-235), the clock machinery has been shown to reg-
ulate GR transcription and activity (illustrated in the
upper part of Figure 4). Via its acetyl-transferase activity,
CLOCK can directly acetylate GRs, thereby reducing
their transcriptional efficiency (236). Furthermore, CRY1
andCRY2 can repressGC transactivation (237). CHRONO
has been shown to interact with both clock proteins and
the GR (238). Together, these processes may produce a
circadian gating of GC signaling in peripheral tissues,
defining a temporal window of sensitivity for GC target
gene regulation (239). Collectively, the functional sig-
nificance of these findings is that optimal physiological
effects of GCs occur when the central signal that controls
the rhythm of GC release and the peripheral rhythms in
tissues expressing GR are aligned.
The actions of GCs within target cells are determined
not only by circulating concentrations and cellular re-
ceptor density, but also by the intracellular conversion of
biologically inactive cortisone to cortisol by the enzyme
11 b-hydroxysteroid dehydrogenase type 1 (HSD-1) and
by the rate of the reverse reaction by the enzyme HSD-2
(see Box 2). In humans and rodents, HSD-1 involved in
the regeneration of GCs is widely expressed throughout
the brain, including in hypothalamic areas, and in many
peripheral tissues, including liver and adipose tissue (37,
240). In some tissues, HSD-1 expression itself is under
circadian control, suggesting that local clock function
may further modulate GR-mediated actions by regulating
the tissue availability of the active hormone (241-243).
The distribution of HSD-1 supports a role for this enzyme
in the regulation of metabolism, appetite, and circadian
rhythms (244).
V. Impact of Circadian Rhythmicity on the
Physiological Effects of Glucocorticoids
The multiple physiological actions of GCs are best de-
scribed as “chronophysiological” because they are gen-
erally strongly modulated by circadian time. In the
sections below, we briefly review the impact of the
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24-hour rhythm of GCs on the stress response, meta-
bolism, cardiovascular function, immune function, and
sleep-wake regulation, as well as memory and learning
processes.
A. The stress response
A commonly used definition of a “stressor” is any
stimulus that disturbs or threatens to disturb the ho-
meostasis and integrity of the individual. The stress re-
sponse is the spectrum of physiological and behavioral
adaptations required to restore homeostasis (Box 1).
Table 3 lists the different domains involved in this
multiplicity, and the list is by no means exhaustive. As
remarked by Koolhaas et al (11), uncontrollability of
exposure to a stressor or failure to cope is the most severe
stressful condition. GC action as part of the stress re-
sponse also displays an impressive diversity because it is
cell-specific and context-dependent in coordinating the
individual response to the challenge (245).
Studies of the HPA response to a stressor have
involved awide variety of experimental challenges as well
as life events. Examples of widely studied stressors and
stress responses in humans include the cortisol awakening
response (a partly predictable mild stressor) (246), high-
intensity exercise (a physical stressor where the cortisol
response facilitates metabolic adaptation but may be
exaggerated by the psychological challenge) (247), dif-
ferent forms of mental arithmetic tasks performed under
direct supervision with or without time pressure, and the
Trier social stress test (TSST), a laboratory test where
cognitive function is challenged in a socially adverse
context (248). A chronic pathological condition that may
arise from inadequate coping with terrifying and often
violent situations is post-traumatic stress disorder (PTSD)
(249). In animal models, a common experimental pro-
cedure to enhance stress responses includes subjecting
pups to prolonged periods of maternal separation, an
emotional and psychosocial condition that may lead to
lifelong adverse health effects (250). During maternal
absence, the pups become more responsive to common
stressors. Acute stress paradigms include the forced
swimming test (an acute exposure to a physical and
psychological challenge that may be perceived as
life-threatening), the restraint or immobilization test (an
exposure to an aversive condition that is often repeated
day after day for extended periods of time), and different
forms of exposure to social defeat (a psychosocial stressor
that is variable in its intensity depending on study con-
ditions). Of note, there have been only a few studies
examining the impact of circadian regulation on the HPA
response to any of these stressors (136, 137, 158–160).
In the traditional conceptualization of stress as the
“flight-or-fight” response, in a first line of defense against
the external stressor, adrenaline and noradrenaline se-
creted from the adrenal medulla increase heart frequency
and blood pressure, improve oxygen uptake in the lung,
and stimulate release of glucose and fatty acids from
body stores, thus fueling energy to organs involved in the
flight-or-fight response, mainly muscles and the brain
(251, 252). Release of cortisol requires de novo bio-
synthesis from cholesterol, thus lagging the autonom-
ically controlled catecholamine secretion by several
minutes. Cortisol frees additional energy by promoting
liver gluconeogenesis (253) and inhibition of insulin
production from the pancreas (254). Its vasoconstric-
tive action further improves blood circulation (255)
and, thus, distribution of oxygen to muscles and the
brain. Central effects include stimulation of cognitive
function and alertness (256).
In rodent models, exposure to a psychosocial stressor
can disrupt overt expression of behavioral circadian
rhythms (257) and of the rhythmof circulatingGC.At the
molecular level, restraint stress and forced swimming
trigger a transient up-regulation of transcription of the
clock gene Per1 in clocks of peripheral tissues and in the
PVN of mice. This transcriptional induction occurs in-
dependently of the time of day, via activation of a GC-
responsive element (GRE) in the Perl promoter region
(191, 258). Activated GR can also increase Per2 tran-
scription, through interaction with BMAL1 (259) and via
down-regulation of Rev-erb a (260).
When stress becomes chronic and cortisol levels stay
elevated, particularly at the time of the usual nadir, some
of the beneficial actions of cortisol become inverted.
Evidence from both rodent and human studies indicates
that chronic exposure to even modestly elevated cortisol
Table 3. The Multidimensional Nature of the So-Called “Stress Response”: Diversity and Multiplicity
Stressors Stress Responses
Main target of exposure to stressor Physical function, cognitive function, emotional regulation, social integration, development,
maturation
Duration of exposure to stressor Acute, single, repeated, prolonged, chronic
Severity of stressor Mild, moderate, severe, life threatening
Timing of exposure to stressor Predictable, unpredictable, dependent on biological time of day, early life, adult life, late life
Type of response to stressor Homeostatic (adaptive, return to baseline set point); allostatic (maladaptive, variable set point)
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concentrations can result in memory deficits, immuno-
suppression, central obesity, as well as cardiometabolic
and reproductive disturbances (161, 261–267). To un-
derstand this switch from protective to damaging effects
of cortisol, the specific roles of both MR and GR in the
various stages of information processing in the brain
should be taken into account. The effect of cortisol on
cognition can turn from adaptive to maladaptive when
actions via the two corticosteroid receptor types are
imbalanced for a prolonged period of time (9).
The term “allostasis” has been coined to refer to the
need to maintain physiological stability (homeostasis) in
the face of continuously changing demands from the
environment (261). Hence, allostasis describes a labile
equilibrium (see Box 1) and is linked to unpredictability
and uncontrollability as characteristic features of a severe
psychological stressor. The term “allostatic load” refers
to the cost of coping with the changing demands and
designates the “wear and tear” that is exerted on organs
and tissues under chronic stress. Cumulatively, allostatic
load predisposes to an increased vulnerability to disease
(268). The allostatic load model of chronic stress includes
the dysregulation of the GC response, which may com-
promise adaptation and resilience to stressful stimuli.
Chronic elevations of GC levels at the time of the normal
trough of the rhythm and the resulting flattening of the
circadian rhythm are hallmarks of “allostatic load.” The
mediating role of misalignment of central and peripheral
oscillators in increasing disease risk is only beginning to
be appreciated.
Several human studies have examined whether there
is a daily variation in the cortisol response to acute
exposure to experimental stressors, such as physical
exercise (269) and psychosocial stressors (248). The
most common hypothesis motivating these studies was
that the stress response would be lower in the morning,
when basal activity is high, than in the evening and early
part of the night, when basal activity is low. Pharma-
cological studies investigating the impact of time of day
on the pituitary-adrenal axis response to CRH stimu-
lation have generally found that the cortisol response is
indeed higher in the afternoon or evening than in the
morning, whereas the ACTH response is similar at both
times of day. The findings are consistent with the ex-
istence of a rhythm of adrenal sensitivity to GC stim-
ulation where sensitivity is higher in the evening, as
demonstrated in several studies of timed exogenous
ACTH administration. When low to moderate intensity
physical exercise was used as a stressor, the findings
regarding an impact of time of day have been mostly
negative, despite the fact that physical performance is
typically better in the afternoon and early evening than
in the morning. However, in studies of high-intensity
exercise, the impact on cortisol levels was clearly highest
in the evening (269). It is thus possible that the impact of
exercise on GC release is dependent on both the psy-
chological effort and metabolic demands of the physical
activity. The HPA response to a psychological stressor
has been best studied using the TSST, a widely used
standardized laboratory stress protocol that induces a
cortisol elevation in a majority of research participants
(248). The results of an analysis of 180 adults who were
submitted to the TSST between 9:45 AM and 7 PM did not
detect significant time of day variations in the response
of free salivary cortisol, total plasma cortisol, or plasma
ACTH. In summary, whereas increasing numbers of
individuals are involved in voluntary physical exercise in
the evening or exposed to psychological stress associated
with fast paced video games, it remains unclear whether
these activities are consistently associated with increased
GC secretion at the time of the habitual nadir, with
potential adverse effects on the synchronization of
central and peripheral circadian clocks.
B. Metabolic regulation
GCs were originally named for their ability to influ-
ence glucose metabolism. To mobilize energy to respond
to a stressor, acute elevations in GC promote glucose
production from the liver after gluconeogenesis (270),
release of free fatty acids from white adipocyte stores
(271), and protein catabolism (272). Under normal con-
ditions, the acute elevation of GC levels toward the end of
the rest period frees energy from internal stores for the
upcoming activity period. The main fuel for the gluco-
neogenetic machinery is pyruvate derived from the deg-
radation of glucogenic amino acids. As a consequence,
chronically elevated cortisol levels promote muscle deg-
radation (273) and elevate blood glucose levels (274).
Because cortisol can also positively stimulate thematuration
of adipocytes from precursor cells (275, 276), it is possible
that chronic cortisol elevation, eg, during repeated stress,
may actively promote the deposition of energy substrates in
white adipose tissues, thus predisposing to adiposity (277).
As summarized in Table 2, peripheral clocks are
present in all tissues that play a major role in glucose
metabolism, including the b-cell, the liver, skeletal
muscle, and adipose tissue, and all these tissues express
type II GR. Misalignment between the rhythm of cir-
culating GC levels and peripheral clocks is thus expected
to have important adverse metabolic effects, which have
indeed been observed in a number of animal studies
(143, 278). In humans, direct experimental evidence was
obtained in a placebo-controlled study where the
24-hour rhythm of cortisol concentrations was flattened
by repeated administration of metyrapone, and the peak
of the rhythm was replaced by a single dose of
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hydrocortisone or placebo given either in the early
morning, near the normal peak time, or in the early
evening, near the normal trough time (279). Figure 10
illustrates the main findings. Starting 4 to 6 hours after
hydrocortisone administration, glucose levels were
higher than under placebo at both times of day; but this
hyperglycemic effect was barely detectable when hy-
drocortisone was given in the morning, whereas it
represented a more than 20% increase in the evening. In
the evening, but not in the morning, the elevation of
glucose was associated with a robust increase in plasma
insulin and insulin secretion rates. The report appeared
in 1999 (279), thus before the identification of pe-
ripheral circadian clocks and their relationship to
metabolism, and it acknowledged that the mechanisms
underlying the evening vs morning differences in
metabolic effects of hydrocortisone “remain to be elu-
cidated.” More recently, an extended laboratory study
in healthy volunteers examined the metabolic effects of
circadian misalignment by imposing a 28-hour sleep-
wake cycle with four meals per 28 hours (23). Figure 11
compares the profiles of cortisol, glucose, and insulin
observed when the subjects had their habitual 24-hour
cycle with those observed when they were sleeping and
eating 12 hours out of phase with the normal schedule.
Circadian misalignment resulted in elevated post-
prandial glucose levels despite increased insulin release,
suggestive of a state of insulin resistance. In laboratory
studies of recurrent sleep restriction, an elevation of
evening cortisol levels has been observed and proposed
as one ofthe mechanisms mediating the concurrent re-
duction in insulin sensitivity (280, 281).
Figure 10.
Figure 10. Mean (1SEM) profiles of plasma cortisol (top panels), insulin secretion rates (ISR, middle panels), and plasma glucose (lower panels) in
nine healthy young men each of whom participated in four studies performed in randomized order. In all four studies, endogenous cortisol levels
were suppressed by metyrapone administration, and caloric intake was exclusively in the form of a constant glucose infusion. Dark horizontal bars
represent the scheduled sleep periods. The daily cortisol elevation was restored by oral administration of hydrocortisone (or placebo—data not
illustrated) either at the normal time of the circadian peak (5 AM, left panels) or 12 hours out of phase (5 PM, right panels). Vertical arrows show
the timing of hydrocortisone administration in each study. Horizontal lines on the ISR and glucose graphs show, respectively, the mean ISR and
glucose levels at the time of hydrocortisone ingestion to facilitate the visualization of post-hydrocortisone changes. The initial effect of the
hydrocortisone-induced cortisol pulse was a short-term inhibition of insulin secretion without concomitant glucose changes, and the magnitude
of this acute effect was similar in the evening and in the morning. At both times of day, starting 4–6 hours after hydrocortisone administration,
there was a delayed hyperglycemic effect that was minimal in the morning but much more pronounced in the evening, when it was associated with
a robust increase in insulin secretion. [Redrawn from L. Plat et al: Metabolic effects of short-term elevations of plasma cortisol are more pronounced in
the evening than in the morning. J Clin Endocrinol Metab. 1999;84(9):3082–3092 (279), with permission. © The Endocrine Society.]
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C. Cardiovascular function
Circadian rhythmicity is present at multiple levels in
the cardiovascular system. Heart rate drops by 15 to
25 bpm during the first half of nocturnal sleep, and this
slowing of the heart rate is only partly related to the
change in behavioral state. Absence or dampening of the
nocturnal dipping of blood pressure, normally a 10–20%
reduction from daytime values, is a predictor of ad-
verse cardiovascular outcomes and mortality (282). A
well-documented study that assessed the temporal profile
of blood pressure under conditions that dissociated be-
havioral and environmental influences from inputs from
the endogenous circadian system showed that there is an
intrinsic circadian rhythm in blood pressure that peaks
around 9 PM and contributes to the magnitude of noc-
turnal dipping by 3 to 6 mm Hg for systolic blood
pressure and 2 to 3 mm Hg for diastolic blood pressure
(283). The risk of adverse cardiovascular events, in-
cluding sudden cardiac death, myocardial infarction, and
syncope, has a robust daily peak in the midmorning,
typically around 10 AM. Moreover, several recent studies
have observed a circadian variation of infarct size in ST-
segment elevation myocardial infarction patients according
to the time of day of the onset of the acute myocardial
infarction (284). Multiple mechanistic pathways have been
identified to explain this 24-hour rhythm in the incidence of
adverse cardiovascular events, including a circadian rhythm
in platelet activation and in prothrombotic plasminogen
activator inhibitor-1 independent of the sleep-wake cycle
(285, 286), a circadian rhythm in cardiac vagal modulation
and in cardiovascular reactivity to exercise and postural
stress (287, 288), and an endogenous circadian-dependent
rhythm in a scale-invariant pattern of heartbeat dynamics
with a morning peak suggestive of increased cardiac vul-
nerability (52).
Importantly, most of the studies exploring the causal
mechanisms of the morning peak in adverse cardiovas-
cular events have used experimental strategies that dis-
sociate the behavioral sleep-wake and rest-activity cycle
from the central circadian signal. Overall, the findings are
consistent with the findings of prospective epidemio-
logical data showing that misalignment of behavioral
Figure 11.
Figure 11. Association between the misalignment of the cortisol profile and reduced glucose tolerance despite increased insulin levels. Mean
(1SEM) 28-hour profiles of plasma cortisol (top), plasma glucose (lower left) and serum insulin (lower right) in 10 healthy adults who participated in
a 10-day laboratory “forced desynchrony” protocol, where sleep (shown by the large vertical gray shaded areas) and meals (shown by the small
vertical gray shaded areas) were scheduled on a recurring 28-hour cycle, a periodicity out of the range of entrainment of the central circadian
pacemaker. Subjects ate four meals (designated as breakfast, B; lunch, L; dinner, D; and snack, S) during each 28-hour “day.” Curves shown in
black represent the profiles observed when the sleep-wake and meal schedules were aligned with the 24-hour cycle, whereas curves shown in
red represent the profiles observed when the 28-hour “day” was 12 hours out of phase with the normal 24-hour day. Cortisol profiles were
inverted during circadian misalignment, demonstrating no adaptation to the 28-hour schedule (as expected from a rhythm controlled by the
circadian pacemaker). The postprandial glucose and insulin responses were significantly increased as compared to normal alignment, and the
differences were also clinically significant. [Redrawn from F. A. Scheer et al: Adverse metabolic and cardiovascular consequences of circadian
misalignment. Proc Natl Acad Sci USA. 2009;106(11):4453–4458 (23), with permission. © National Academy of Sciences.]
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rhythms relative to the endogenous clock as occurs in
shift workers is associated with an increased incidence of
cardiovascular disease (289).
The existence of a circadian clock in cardiac tissue is
well established. Based on the response of tissue cultures
from mice carrying bioluminescent reporters of the core
clock genes, it appears that both the amplitude and the
phase of the atrial circadian rhythm of PER2::LUC is
affected by dexamethasone treatment as well as by the
timing of medium treatment. Furthermore, the phase
responsewas different from that observed in the liver, and
Per1 and Per2 peaked approximately 3 hours earlier in
the liver than in the heart (220), suggesting that a normal
rhythm of GC signaling may be an important mechanism
to entrain the circadian clock in cardiomyocytes and to
maintain an optimal internal phase relationship with
other peripheral clocks. Consistent with this concept,
induction of the GC-sensitive Per2 in mice during
myocardial ischemia was associated with a switch from
fatty acid to glucose metabolism with cardioprotective
effects, including a smaller infarct size (290).
D. Immune function
From a pharmacological perspective, one of the most
interesting aspects of GCs is their high immuno-
suppressive potential (291). Cortisol prevents prolif-
eration of T cells by rendering the T cells resistant to
In-terleukin-1 and unable to produce the T-cell growth
factor (292). It further has a negative-feedback effect on
Interleukin-1 expression and release in monocytes (293).
GCs promote the redistribution of lymphocytes from the
intravascular compartment to the lymph nodes, spleen,
and bone marrow (294). Actions on b-cells include in-
hibition of Ig biosynthesis through the nuclear factor-kB
pathway and induction of apoptosis. Furthermore, cor-
tisol inhibits monocyte differentiation and macrophage
phagocytosis and cytotoxic activity (295).
It is well established that multiple components of the
immune system, from both the innate and adaptive
systems, undergo robust circadian oscillations (296).
Collectively, these oscillations are thought to optimize the
response of the host to pathogen encounters and to
promote recovery. The circadian organization of the
immune system impacts vulnerability to disease, disease
severity, and efficacy of therapeutic interventions. The
best-characterized circadian rhythm in the immune sys-
tem is that of the number of circulating leukocytes in
blood, which peaks during the resting phase (nocturnal
sleep in humans) for most subtypes but during the active
phase for some of them. Leukocytes that are most
abundant in blood during the night are negatively reg-
ulated by GC levels. The early morning rise of cortisol
facilitates the redistribution of these cells to the bone
marrow, with a delay of approximately 3 hours.
Autonomous circadian clocks have been identified in a
number of immune cells, including macrophages (297)
and lymphocytes (298, 299). Recent work has identified a
circadian clock in epithelial club cells of themouse lung as
well as an interaction between this clock and GCs that
could explain the known rhythmic variations in symptom
severity and lung function in inflammatory lung diseases
such as chronic obstructive pulmonary disease and
asthma (218). In normal mice exposed to infection, there
is a circadian variation in neutrophil recruitment to the
lung that is driven by the rhythmic expression of the
chemokine CXCL5, itself under GC control. Genetic
ablation of the circadian clock within bronchoalveolar
cells results in enhanced and arrhythmic CXCL5 ex-
pression, despite normal rhythmicity of circulating GC
and of GR occupancy. These genetically manipulated
animals no longer respond to the anti-inflammatory
action of dexamethasone.
E. Arousal
The regulation of physiological and psychological
arousal across the 24-hour cycle is one of the most
common interpretations of the functional significance of
the rhythm of HPA activity. The rapid rise of HPA ac-
tivity and GC levels after the first few hours of sleep is
generally thought to prepare the brain for cognitive ac-
tivity and to prepare the periphery, including the liver,
muscle, and adipose tissue, for impending meal intake
and physical activity (107). As the day progresses, the
slow decline toward evening quiescence prepares instead
for the initiation of sleep. An important interaction in the
control of arousal is the reciprocal excitatory feedback
between HPA activity controlled by the PVN and nor-
epinephrine release from the brainstem locus coeruleus.
CRH activates the locus coeruleus to release norepi-
nephrine, which in turns activates hypothalamic CRH.
Appropriately timed normal sleep enhances the am-
plitude of the rhythm of HPA activity and stabilizes its
phase (illustrated in Figure 8). Under normal conditions,
the initiation of sleep occurs when HPA axis activity is
near nadir levels and the circadian rise of ACTH and
cortisol occurs roughly 2–3 hours after sleep onset, in
parallel with an increased propensity for rapid eye
movement (REM) sleep. When sleep is initiated at an
abnormal time of day, an acute inhibitory effect is exerted
on GC levels, and this appears to be mediated by deep
non-REM (NREM) sleep. Nighttime awakenings co-
incide with cortisol pulses and CRH release and are
followed by a temporary inhibition of cortisol secretion
(300). Upon final morning awakening, cortisol levels
generally show a rapid rise that may continue for about 1
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hour. This phenomenon is called the cortisol awakening
response and appears to be independent of circadian
regulation (246). The combination of the sleep onset
inhibition of HPA activity with the post-awakening
stimulation enhances the amplitude of the human cor-
tisol rhythm by about 15% (113).
F. Memory and cognition
The importance of circadian fluctuations in GC levels
for memory and learning has been highlighted by a recent
study by Liston et al (301). The authors studied trans-
genic mice with fluorescent neurons in the motor cortex
of the brain, enabling them to study the effects of cir-
cadian GC exposure on neuronal structure in vivo. High
levels of GCs at the time of learning (for example, during
the evening circadian peak in this nocturnal species)
were associated with improved learning of motor skills
and increased spine formation in cortical neurons. This
process was mediated via rapid nongenomic GR action.
Low levels of GCs during circadian troughs, however,
were required for memory consolidation in the days after
learning. This stabilization process depended on the
“pruning” of older spines by MR-mediated changes in
gene expression (301). The study by Liston et al (301)
used the synthetic GC dexamethasone to suppress HPA
axis activity and circulating corticosterone levels.
Dexamethasone targets the pituitary corticotrophs (302).
The brain is resistant to penetration by dexa-methasone
because it is a substrate for multidrug resistance
P-glycoprotein at the level of the blood-brain barrier
(303). The brain and in particular the MR is therefore
depleted of corticosterone. Intermittent administration of
corticosterone to these dexamethasone-treated animals
appeared to be a prerequisite to promote learning-
dependent plasticity (304).
In line with the work by Liston et al (301), Rimmele
et al (305) have shown that blocking the circadian rise of
cortisol in the early morning in humans using high-dose
metyrapone impaired memory retrieval of emotional and
neutral texts and pictures learned 3 days earlier. Of note,
the suppression of cortisol levels by metyrapone is
achieved by inhibition of the enzyme 11-b hydroxylase,
resulting in high levels of 11-deoxycortisol, a steroid that
has mineralocorticoid activity. A placebo-controlled
study showed that cortisol infusion during a daytime
nap as compared to a period of wakefulness at the same
time of day had opposite effects on consolidation of
memory of temporal sequence (306). Another study
suggested that memory formation during sleep may be
impaired by both insufficient MR activation and GR
overactivation (307). Overall, the physiological rhythm
in circulating GCs appears to improve memory function.
Fluctuations in GR and MR signaling regulate plasticity
in memory-encoding brain regions. This might have
important implications for the timing for GC therapy.
These findings also provide a possible explanation for the
impairment of cognitive function observed in patients
with Cushing’s syndrome (see Section VI. D) and in in-
dividuals with nonchronophysiological synthetic GC
replacement therapy (308).
VI. Conditions of Abnormal Circadian
Rhythmicity of Circulating Glucocorticoids
Three types of mechanisms resulting in abnormal GC
rhythms can be distinguished. First, the master circadian
clock in the SCN is altered. The best-documented con-
dition falling in this category is aging. Second, the master
circadian clock is not altered, but the GC rhythm is
disrupted by behavioral or pathophysiological factors.
Figure 12.
Figure 12. Impact of age on the 24-hour profile of plasma cortisol in healthy nonobese men. Data are shown at each time point as mean 1 SEM.
The two age groups included eight men that were matched for body mass index. Note the higher nadir level, the reduced amplitude of the
overall rhythm, and the earlier onset of the early morning rise in older participants. The overall disruption of the 24-hour cortisol profile is likely to
contribute to and/or exacerbate age-related metabolic, immune, and cognitive deficits. [Redrawn from E. Van Cauter et al: Age-related changes
in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861–868 (313),
with permission. © American Medical Association.]
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This category includes shift work, an increasingly com-
mon condition, sleep disturbances, clinical sleep disor-
ders, fatigue, and chronic stress conditions. Third, the
master clock is not altered, but the GC rhythm is pro-
foundly abnormal due to Cushing’s syndrome, adrenal
insufficiency, or chronic treatment with synthetic GC.
A. Aging
With advancing age, a number of behavioral and
physiological human circadian rhythms are disrupted.
There is good evidence that the reduced amplitude of
multiple daily cycles and the increased prevalence of sleep
disturbances in older adults are associated with neuronal
degeneration in the SCN, the master clock (309).
However, the intrinsic period of the human circadian
pacemaker does not seem to be affected by age (310) .
The senescence of the circadian system is more pro-
nounced in Alzheimer’s disease than in normal aging
(311, 312).
Commonly observed changes of HPA axis activity in
older adults indeed include reduced amplitude of the
24-hour cortisol profile, mostly due to an elevation of the
nadir, and decreased reactivity and resilience to stressors.
Figure 12 illustrates the mean 24-hour profile of plasma
cortisol from a group of 17- to 24-year-old men as
compared to that collected in a group of healthy non-
obese 70- to 83-year-old men. The dampening of the
rhythm, the higher nadir level, and earlier timing of the
onset of the circadian rise are readily apparent. Thus, in
old age, the 24-hour rhythm of GC provides a weaker
synchronizing signal for central and peripheral clocks.
With aging, evening cortisol levels increase progressively
in both men and women (313), and this may lead to an
overall increase in mean 24-hour levels (314). Interestingly,
the chronology of appearance of this disturbance of the
cortisol rhythm is similar to that observed for the age-
related decrease in REM sleep, with both alterations
developing from midlife to old age (313). The age-related
elevation of the cortisol nadir is consistent with a reduced
resilience of the HPA axis to a challenge, with slower
recovery, and could facilitate the development of central
and peripheral disturbances associated with GC excess,
including memory deficits, insulin resistance, and oste-
oporosis. A recent metaanalysis of HPA function and
physical performance shows that a greater decline of
HPA activity across the daytime (ie, likely to reflect a
greater amplitude of the rhythm) is associated with better
physical performance in later life (315). These findings
are consistent with observations from the Whitehall II
study where “raised curves of saliva cortisol” with a
flatter pattern of release were associated with older age
and impaired physical functioning (316).
B. Shift work
Circadian disturbances triggered by conflicting syn-
chronizing cues (eg, rotating shift work, recurrent jet lag)
are now considered as pathogenic when recurring on a
chronic basis. Irrespective of their work schedule, the
circadian system of shift workers rarely adapts to the
behavioral rest-activity cycle because the vast majority
of shift workers revert to daytime activities during
non-work days. Shift work is associated with a higher
incidence of obesity, cardiovascular disease, sleep dis-
turbances, impaired immune function, and cancer (317,
318). Of note, most of these conditions may also arise
from disruption of the circadian system—at least in animal
models (319, 320). Shift work disorders usually manifest
only after several years of shift work, but this may be
partly due to the fact that individuals who are shift work
intolerant and prone to quickly develop adverse effects
tend to return to regular daytime working schedules.
Under conditions of shift work, central and peripheral
oscillators dissociate, which leads to a misalignment of
daily rhythms in physiological functions (321–324), in-
cluding endocrine axis regulation and melatonin. Syn-
chronization during shift work can be improved by
melatonin supplementation, adequately timed exposure
to light and/or dark, and manipulation of the timing and
composition of food intake (321, 325–329). Depending
on the shift schedule, GC rhythms can partly adapt.
Urinary cortisol in night shift workers has been reported
to rise by 16% during daytime sleep and to decrease by
13% during nighttime sleep on the off-nights. Morning
serum cortisol is reduced compared to day shift workers
(330). It remains to be shown whether this is primarily an
adaptation to shifted activity and/or meal timing or re-
flects increased stress exposure during work hours. Given
the role of GCs in systemic circadian alignment (187,
190), manipulating the 24-hour cortisol profile in shift
workers may have preventive potential against some of
the adverse health effects of shift work (227). In a mouse
model, this strategy was shown to accelerate adaptation
to jet lag (190).
C. Sleep disturbances, clinical sleep disorders, and fatigue
There is a bidirectional relationship between HPA
activity and sleep. On the one hand, excessive HPA ac-
tivity promotes sleep fragmentation, resulting in shallow
and insufficient sleep. On the other hand, insufficient
sleep and poor sleep quality can result in elevated GC
levels, particularly in the late afternoon and early evening
when the HPA axis is normally quiescent to facilitate
sleep onset and maintenance. Under chronic conditions,
this vicious cycle can be difficult to interrupt. In labo-
ratory studies, sleep deprivation, whether total or partial,
acute or recurrent, has been associated with an elevation
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of HPA activity in the late afternoon and evening hours
(117, 280, 281, 331). Thus, sleep loss appears to delay the
return to quiescence of the HPA axis, similar to aging
(332). Chronic insomnia with an objective reduction of
total sleep time is associated with higher cortisol levels
across the later part of the day and the night (165). This
relative ambient evening hyper-cortisolism appears to
play a role in the effects of sleep deprivation on gene
expression in the brain (333). An elevation of daytime
cortisol secretion has been observed in some (334, 335),
but not all (336), studies of patients with obstructive sleep
apnea. Well-documented studies have found positive
effects of continuous positive airway pressure treatment
(185, 334, 335, 337). It has been proposed that dys-
functional HPA axis activity (eg, by chronic stress or due
to adrenal hyperfunction; see Section VI. D and E) may
play a role in promoting sleep disorders such as insomnia,
but that HPA axis dysfunction may also be the conse-
quence of a sleep disorder, as could be the case for ob-
structive sleep apnea (300, 338, 339). Of note, multiple
reports have documented alterations of the cortisol
rhythm in obesity and type 2 diabetes (340, 341).
However, none of these studies controlled for the pres-
ence of obstructive sleep apnea. A study using frequent
sampling of saliva melatonin under dim light conditions
found no difference in the timing of nocturnal melatonin
release in patients with sleep apnea as compared to
controls (342), suggesting that the phase of the master
clock is not affected by this sleep disorder.
Because of its lipophilic nature, cortisol readily pen-
etrates the blood brain barrier and exerts numerous ef-
fects, in particular on sleep regulation. Conditions of
hypercortisolism, whether due to a pathology or due to
exogenous administration, are therefore associated with
sleep disturbances. In Cushing’s syndrome, deep NREM
sleep is reduced, but interestingly, in patients with pituitary-
dependent disease, adrenal secretory activity is still initiated
predominantly during NREM sleep, suggesting the per-
sistence of a link between pulsatile cortisol release and the
ultradian NREM-REM cycle (339, 343). Exogenous GCs,
both natural and synthetic, taken near bedtime inhibit REM
sleep. Hydrocortisone appears to stimulate slowwave sleep,
whereas syntheticGCs such as dexamethasone inhibit slow-
wave sleep (339, 344, 345).
Sleepiness is a condition where there is increased
pressure to sleep and sleep will be easily initiated when
an opportunity presents. In contrast, fatigue describes a
condition of tiredness, exhaustion, and/or low energy
but without increased pressure to sleep (346). Chronic
fatigue syndrome is often associated with alterations in
HPA axis activity such as mild hypocortisolism, atten-
uated amplitude of cortisol rhythm, enhanced negative
feedback to the HPA axis, and blunted HPA axis re-
sponsiveness (347). A similar constellation of alterations
of GC regulation may be seen in PTSD (249). In
fibromyalgia, one study observed a slower decline of
cortisol levels across the daytime period, with elevated
concentrations (348), but another report found no
Figure 13.
Figure 13. Comparison of the 24-hour profile of plasma cortisol in normal nonobese adults (left), patients with pituitary-dependent Cushing’s
disease (center), and patients with untreated major depression of the unipolar subtype (right). For each condition, a representative example is
shown in the top panel and mean (1 SEM) profiles from eight to 10 subjects are shown in the bottom panel. [Redrawn from E. Van Cauter:
Physiology and pathology of circadian rhythms. In: Edwards CW, Lincoln DW, eds. Recent Advances in Endocrinology and Metabolism. Vol. 3.
Churchill Livingstone, Edinburgh, UK, 1989:109–134 (435), with permission.]
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evidence for disturbances of the 24-hour GC profile
(349). All these conditions frequently include sleep
disturbances, but there is no evidence for alterations in
central pacemaker function. Whether eliminating or
reducing the sleep disturbances could reduce the severity
of the other neuropsychiatric and somatic symptoms is
still an open question.
D. Cushing’s syndrome, adrenal insufficiency, and
glucocorticoid therapy
1. Cushing’s syndrome
Adrenal hyperactivity, caused by tumors of the pitu-
itary or the adrenal cortex, is characterized by central
obesity, hirsutism, moon face, plethora, several car-
diometabolic disturbances (including hypertension,
glucose intolerance, and dyslipidemia that result in an
increased cardiovascular risk), osteoporosis, and mul-
tiple psychiatric abnormalities. Adrenal hyperactivity is
referred to as Cushing’s syndrome, irrespective of the
etiology (350). Cushing’s disease refers to secondary
hypercortisolism derived from ACTH overproduction
in the pituitary (351). A low amplitude circadian varia-
tion may persist in some patients with pituitary-dependent
Cushing’s disease, but overall circadian modulation is
absent (Figure 13, middle panel). Cortisol pulsatility is
blunted in about 70% of patients with Cushing’s disease,
suggesting autonomous tonic secretion of ACTH by a
pituitary tumor. However, in about 30%of these patients,
the magnitude of the pulses is instead enhanced (352).
These “hyperpulsatile” patterns could be caused by en-
hanced hypothalamic release of CRH or persistent pitui-
tary responsiveness to CRH.
In patients with primary adrenal Cushing’s syndrome,
increased cortisol secretion appears to result from both
increased basal secretion and increased pulse frequency
(353). A partial persistence of cortisol rhythmicity has
rarely been observed, but when present, it could be
mediated by the neural pathway between the SCN and
the adrenal cortex (106). SCN function is not affected by
the hypercortisolism of Cushing’s syndrome, consistent
with the absence of GR expression in this neural tissue
(Table 1). Circadian phase, as assessed by dim light
melatonin onset (DLMO), has been examined in patients
with Cushing’s syndrome of both adrenal and pituitary
origin, and no differences from controls were de-
tected (354). It has been suggested that alterations in the
24-hour GC rhythm may actually serve as an early
preclinical marker for adrenocortical tumors (119, 355,
356). This is also the case for pituitary ACTH-secreting
tumors, where one of the first clinical abnormalities is the
elevation of the nocturnal nadir of cortisol.
The absence or the marked dampening of cortisol
circadian variations in Cushing’s syndrome has obvious
diagnostic implications because the time of day when
blood samples are obtained has to be taken into account
in the evaluation of the result. Differentiation between
normal and pathological levels is greatly improved by
adequately selecting the sampling time because the
overlap between normal individual values and values in
patients with Cushing’s syndrome is minimal during a
4-hour interval centered around midnight (113). The
reduced amplitude of the circadian cortisol rhythm as-
sociated with higher nadir levels is, in clinical practice, an
early marker of hypercortisolism in humans, and the
evaluation of cortisol levels during the normal nadir of
the rhythm is a common screening test to diagnose
Cushing’s syndrome (357). Moreover, the gradual re-
covery of a normal circadian variation in circulating
cortisol levels is also a clinical marker of the cure of
Cushing’s syndrome, reflecting a normalization of the
entire neural regulation of the HPA axis. In contrast, the
persistence of a dampening of the cortisol rhythm, even
when absolute cortisol concentrations in blood or urine
are within the normal range, usually predicts a relapse of
the disease (358).
Lastly, Cushing’s syndrome may also result from ec-
topic ACTH secretion from a nonpituitary tumor. In this
case, ACTH release from the tumor is not under circadian
control, and reproducible 24-hour variations in GC are
not detectable.
2. Adrenal insufficiency
Primary hypocortisolism, or Addison’s disease is
mainly due to autoimmune defects (70% of all cases), but
it can also be caused by infections such as tuberculosis,
HIV, fungi, or cytomegalovirus that can result in direct
destruction of the adrenal cortex (359). In many cases,
hypocortisolism is only diagnosed when patients present
with an acute crisis during an intercurrent disease. Daily
rhythmicity of circulating ACTH and cortisol is generally
absent or blunted in Addison’s patients (360). Severe
fatigue is present in about half of the patients and is
associated with sleep disturbances (339, 361). Basal
concentrations of GCs are a poor diagnostic indicator of
Addison’s disease. Thus, direct ACTH stimulation tests
are necessary to assess adrenal functionality. Secondary
partial hypoadrenalism, due to ACTH deficiency, is more
difficult to detect, and its diagnosis often requires indirect
measures such as the insulin tolerance test (359). In
patients with either primary or secondary adrenal fail-
ure, inadequate replacement of GCs may lead to hy-
potension, diarrhea, abdominal pain, weight loss, poor
stress responses, and electrolyte abnormalities. Conversely,
overdosing with GCs without respecting the physiological
daily rhythm will promote Cushing’s-like features such
as glucose intolerance, hypertension, and cardiovascular
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disease, as well as osteoporosis and disturbances of the
immune system (362–365). There is evidence that the
commonly used hormonal replacement therapy in patients
with adrenal failure does not mimic the physiological
circadian rhythm of cortisol secretion, resulting in a non-
physiological plasma cortisol profile, as well as a risk of
over- or under-replacement, associated with increased
morbidity and premature mortality (366). Thus, as will be
discussed further in Section VII, mimicking the circadian
profile of cortisol blood levels may help to minimize side
effects and increase the quality of life in patients with
adrenal insufficiency (367, 368).
3. Glucocorticoid therapy
About 1% of the Western world receives therapy with
potent synthetic GCs resulting in supraphysiological
exposure. During treatment, patients suffer a 2-fold
higher risk of depression; a 4-fold higher risk of mania,
delirium, confusion, or disorientation; and nearly a 7-fold
higher risk of suicide (369). Moreover, cessation of GC
therapy may result in enduring psychiatric complaints
(370). One possible cause of GC-induced psychopa-
thology is the suppression of the episodic secretion of
the endogenous GC over the 24-hour cycle and after
stress. Continuous exposure to synthetic GCs may
cause desensitization and reduced responsiveness of
GR-dependent neuronal networks. When synthetic GCs
such as dexamethasone, prednisone, and related steroids
that have limited brain penetration are used, the de-
pletion of endogenous hormone levels may cause a
hypocortisolemic state in the brain, in particular with
respect to the lack of MR and episodic GR activation
(304, 371). Hence, a severe MR:GR imbalance may
develop during synthetic GC therapy. Replacement with
cortisol mimicking the circadian pattern to restore the
receptor balance may therefore help to ameliorate the
side effects of potent synthetic GCs (36).
E. Depression and post-traumatic stress disorder
Two types of depression are distinguished in the Di-
agnostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-5), namely melancholic depression and
atypical depression. The two subtypes are characterized
by opposite alterations in HPA axis activity and in cir-
cadian expression of the severity of the symptoms (372).
Hypercortisolism with persistent circadian rhythmicity
and increased pulsatility is found in a majority of severely
depressed patients, particularly those with melancholic
features who have more severe symptoms in the morning
(373–375). Cortisol profiles are illustrated in Figure 13
(right panels). These patients do not develop the clinical
signs of Cushing’s syndrome despite the high circulating
cortisol levels, possibly due to the GC resistance
characteristic for these patients. The quiescent period of
cortisol secretion is shorter and more fragmented, and it
often starts later and ends earlier than in normal subjects
of comparable age. These alterations could reflect the
impact of sleep disturbances (low amounts of deep slow-
wave sleep and reduced latency to REM sleep) as well as
an advance of central circadian phase. When a clinical
remission of the depressed state is obtained, the hyper-
cortisolism and the alterations in the quiescent period
disappear, indicating that these disturbances are state-
dependent, rather than trait-dependent (376).
Atypical depression is in some of its symptomatology
the opposite of melancholic depression. The symptoms
display a 24-hour variation, with the worst presentation
in the evening. Atypical depression is characterized by
lack of energy, fatigue, hypersomnia, and unexplained
weight gain. The activity of the HPA axis is reduced
rather than enhanced, reflecting a hypofunction of CRH
neurons in the PVN resulting in reduced circulating levels
of cortisol (372). Blunted HPA activity can be associated
with a dampening of the circadian variation (375, 377). It
is often difficult to distinguish cause and effect in cases of
atypical depression. Chronic stress or traumatic events
may have led to elevated cortisol levels and blunted
circadian rhythmicity, which then triggered the disease
outbreak. On the other hand, the social disapproval that
is often perceived by sufferers of mental disorders added
to the sleep-wake problems may become stressful in a
depressive person, thus interfering with normal circadian
cortisol responses. Given the role of GCs in regulating
sleep (see Section VI. C), it may be of clinical interest to
determine the extent to which stabilization of the circa-
dian cortisol profile and correction of sleep disturbances
may ameliorate the symptoms (378, 379).
Circadian secretion of cortisol in chronically stressed
humans is also dampened due to higher levels during the
habitual daily nocturnal trough, an alteration identified
as a risk factor for insulin resistance, obesity, andmemory
impairment (380). A meta-analysis of 47 studies ana-
lyzing cortisol effects in PTSD found lower basal morning
cortisol levels in individuals with PTSD than in controls
not exposed to trauma, irrespective of the presence of
major depression as a comorbid factor (381). Afternoon
and evening levels were also lower in PTSD subjects with
comorbid major depression who had higher levels of
cortisol at that time of day. Although findings are highly
heterogeneous, it appears that some dampening of the
circadian variation of cortisol may be present in many
cases, and this is most clearly seen in those with a more
severe condition (382). The paradoxically lower cortisol
levels found inmultiple studies of PTSD are interpreted as
reflecting an increased sensitivity to negative feedback
regulation of HPA activity (249). Lower cortisol levels
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were also found in PTSD females, eg, after physical or
sexual abuse. These findings suggest that enhanced HPA
negative feedback regulation may be a marker of trauma
exposure rather than a specific mechanism of vulnera-
bility for PTSD, whereas lower daily cortisol output may
be associated with PTSD in particular (381, 382). Of
note, the timing of the onset of nocturnal melatonin
release, a marker of central circadian phase, is similar in
subjects affected by PTSD and in well-matched con-
trols (383).
F. Eating disorders
Abnormal eating behavior manifests in pathologies
such as anorexia nervosa, bulimia nervosa, night- and
binge-eating syndromes, all of which display signs of
circadian disruption. Anorexia nervosa is defined by a
general restriction of food intake resulting in a low body
weight, whereas a hallmark of bulimia nervosa is ex-
cessive bouts of uncontrolled eating followed by purging.
Both patient groups often show confounding symptoms
of depression, which has been closely associated with
disruption of cortisol rhythms (see Section VI. E). In
anorectic patients, total plasma cortisol levels as well as
free saliva cortisol levels are elevated; the circadian
variation persists but can be dampened (384, 385). In-
terestingly, cortisol perturbations can be reversed after
refeeding, perhaps suggesting that the hypercortisolism is
due to metabolic stress as a consequence of low adiposity
(384, 386, 387).
Binge-eating disorder is very close to bulimia nervosa
but does not involve postprandial purging. Few studies
have characterized endocrine rhythms in these patients,
and the results are somewhat conflicting. Mechanisms
underlying the night-eating syndrome are also unclear.
One possible pathway is that the night-eating behavior
itself causes misalignment in the circadian clock system,
culminating in metabolic perturbations. Vice versa, cir-
cadian disruption may promote the development of night-
eating syndrome, eg, as a consequence of altered cortisol
and melatonin rhythms. In patients suffering from night-
eating syndrome, the nocturnal melatonin peak is delayed
(388), resulting in elevated morning melatonin levels (389).
Peak cortisol levels are either reduced in patients with
night-eating syndrome (388, 389) or increased (390).
VII. Manipulating the 24-Hour Rhythm of
Circulating Glucocorticoids to Optimize
Circadian Alignment
A. Chronopharmacology of conditions of excessive cortisol
production: An untapped opportunity?
The most common disturbance of the human cortisol
rhythm, observed in a wide variety of conditions, is
abnormally elevated afternoon and evening levels. In the
mean profiles shown in Figures 12 and 13, it can be seen
that morning levels in older adults, patients with Cush-
ing’s disease, patients with untreated major depression,
and primary insomniacs with short sleep duration
overlap with levels observed in normal young adults. In
contrast, the evening levels are clearly elevated and, as
discussed above, are likely to impair sleep duration and
quality and perpetuate a feed-forward loop further
compromising the return to quiescence of the HPA axis
on the following day. This suggests that normalization of
the 24-hour cortisol profile should target the evening
period to recreate the physiological quiescent period.
Acute pharmacological suppression of cortisol levels at
specific times of day has been used in healthy human
adults to elucidate metabolic (279) and cognitive impli-
cations of cortisol rhythmicity (305, 306, 391). These
studies used metyrapone, an inhibitor of cortisol bio-
synthesis with a rapid onset of action and biological half-
life of about 2 hours, or the GC receptor antagonist
mifepristone. As expected, the dose of metyrapone
needed to suppress physiological cortisol levels was much
lower in the evening (500 mg) than in the morning (3 g).
Pharmacological suppression of cortisol levels or action
has also been explored in a variety of pathological
conditions including patients with Cushing’s disease in
whom hypercortisolism could not be controlled by a
surgical intervention (392, 393), and more recently in
patients with treatment-refractory depression (394) or
type 2 diabetes (395). A recently published multicenter
retrospective study assessed the effectiveness of metyr-
apone in controlling cortisol excess in a large series of
patients with Cushing’s syndrome and concluded that
metyrapone is an effective therapy for short- and long-term
control of hypercortisolemia (396). Surprisingly, it seems
that none of these recent trials targeted evening, rather
than daytime, cortisol levels or action.
B. Chronopharmacotherapy of adrenal insufficiency
GC replacement therapy has drastically improved
survival and reduced morbidity in patients with adrenal
insufficiency who, until about 1949, ie, before the era of
hydrocortisone substitution, would have faced an aver-
age survival span after diagnosis of just 1–2 years (397).
But still, excess morbidity and mortality of patients with
adrenal insufficiency on GC replacement persists even
under state-of-the-art replacement regimens. Mortality
risk remains elevated more than 2-fold (33), and ample
evidence documents increased long-term morbidity in
patients with adrenal insufficiency of any cause, with an
excess risk of cardiovascular disease (33, 398, 399),
psychological disorders (400), and a significant negative
impact on health-related quality of life (401, 402).
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Major treatment goals of GC substitution for adrenal
insufficiency include the recreation of physiological
24-hour cortisol exposure profiles in the circulation and
at target organs to guarantee adequate stress reactivity,
avoiding life-threatening acute adrenal insufficiency, and
preventing symptoms and adverse consequences of
chronic adrenal insufficiency, eg, fatigue, nausea, and
weight loss (403). At the same time, care must be taken to
administer as little hydrocortisone as possible to avert
detrimental psychological, metabolic, and cardiovascular
side effects of iatrogenic GC excess (404–406). This
delicate balance between overtreatment and undertreat-
ment of adrenal insufficiency makes reliable monitoring
instruments very desirable. Current evaluation of treat-
ment adequacy is based primarily on clinical criteria
including changes in weight, blood pressure, electrolyte
levels, and quality of life assessments (401, 402). A sig-
nificant problem in using clinical criteria as the sole
monitoring instrument and guide to treatment lies in the
fact that clinical evidence for GC overdose (eg, glucose
intolerance, weight gain, trophic skin changes) or GC
under-replacement (eg, daytime fatigue, diarrhea, and
nausea) lacks specificity. Therefore, biochemical moni-
toring in the form of blood (407) or salivary cortisol (408)
profiles has been employed to assess the adequacy of GC
replacement. The validity of using daytime profiles of
salivary cortisol for monitoring GC substitution regimens
is still controversial. Ceccato et al (408) found that two
salivary cortisol measurements in patientswith secondary
adrenal insufficiencywere as good as sixmeasurements to
predict the area under the curve during oral treatment
with cortisone acetate. The same authors have suggested
that a single measurement of saliva cortisol upon awak-
ening can facilitate the diagnosis of adrenal insufficiency
(408). In contrast, Thomson et al (409) found a significant
interindividual variation in plasma and salivary cortisol
profiles subsequent to oral hydrocortisone treatment for
adrenal insufficiency of primary or secondary origin.
Furthermore, resulting plasma and salivary cortisol levels
correlated only poorly, leading the authors to conclude
that salivary cortisol measurement is not a sufficient
tool for monitoring the adequacy of hydrocortisone sub-
stitution. In contrast, more recent work found an excellent
correlation between levels of total cortisol in plasma and
free cortisol in saliva, both sampled at 20-minute intervals
from early afternoon until bedtime in healthy young adults
(illustrated in Figure 6) (117). In a direct comparison, Arlt
et al (363), correlating a self-developed clinical score to
timed cortisol serum measurements in the assessment of
GC replacement quality, found that three timed cortisol
serummeasurements were of very limited practical value in
guiding replacement therapy because cortisol levels of
patients determined as under- and oversubstituted with
cortisone acetate largely overlapped with those of well-
replaced patients. Unfortunately, the most precise method
of gauging the adequacy ofrecreating physiological, cir-
cadian systemic cortisol profiles remains highly repetitive
blood or saliva sampling, which, due to cost and labor,
does not represent a feasible, clinical biomarker. In sum, the
existing monitoring tools are far from perfect in accurately
assessing treatment quality, emphasizing the importance of
characterizing new biomarkers of treatment quality.
Figure 14.
Figure 14. A, Comparison between 24-hour plasma cortisol profile typically achieved with optimal hydrocortisone replacement (10 mg upon
awakening, 5 mg at lunch, and 5 mg at 7 PM [dinner]) in patients with adrenal insufficiency (dotted red lines) and normal cortisol levels from
healthy young adults (shaded area) (data source, Refs. 313 and 416). B, Profile of circulating cortisol levels achieved by a single early morning
administration of a modified-release oral hydrocortisone preparation (solid line) as compared to the profile resulting from immediate release
hydrocortisone administered three times daily (dashed line). [Redrawn from G. Johannsson, et al: Improved cortisol exposure-time profile and
outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin
Endocrinol Metab. 2012;97(2):473—481 (416), with permission. © The Endocrine Society.] C, Example of a plasma cortisol profile obtained in
a healthy subject in whom endogenous cortisol levels were suppressed by 5 days of metyrapone administration and replaced by sc hydrocortisone
replacement via an infusion pump programmed to mimic circadian and pulsatile variations. [Adapted from G. M. Russell, et al: Subcutaneous
pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014;81(2):289–293 (422), with permission. © Blackwell Scientific
Publications.]
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Conventional pharmacotherapies of adrenal insuf-
ficiency for prolonged periods of time often have ad-
verse side effects, such as osteoporosis, altered glucose
and fat metabolism, and increased cardiovascular risk,
mainly due to overtreatment.Moreover, the conventional
hormone replacement therapy does not significantly
protect the patient against the threat of acute adrenal
crisis caused by undertreatment. Therefore, optimization
of GC replacement therapy remains a challenging task for
endocrinologists. One promising aim to limit side effects
and improve quality of life of hypocortisolic patients
might be the restoration not only of physiological levels
of circulating cortisol, but also of its circadian (ie, an-
ticipating dawn as in normal subjects) and pulsatile
dynamics (410–412). Current typical hydrocortisone
substitution regimens consist of 15–25 mg administered
orally every 24 hours, generally in two or three divided
doses, and this substitution regimen is often in excess of
the physiological cortisol production of healthy subjects
(approximately 3 to 12 mg/m2 per 24 hours) (2, 3).
Disadvantages of these standard replacement regimens
include nonphysiological cortisol serum profiles with
acute large elevations after the midday and afternoon
doses as well as subphysiological cortisol concentrations
before the administration of the subsequent dose (illus-
trated in Figure 14A). Furthermore, the vast majority of
patients report that multiple daily dosing is problematic,
with difficulties related to forgetting doses, particularly at
midday and in the afternoon (413). Furthermore,missing a
dose results in fatigue and exhaustion and taking a dose
too late in the day causes sleep problems. Overall, the
nonphysiological 24-hour profiles of circulating GC
resulting from prescribed multiple dosing are likely to
contribute to excess mortality in GC-treated patients with
adrenal insufficiency (411, 414). Thus, the improved ap-
proximation of the circadian cortisol rhythm has recently
emerged as a novel and important target in the im-
provement of GC therapy.
Toward this goal, a dual-release oral hydrocortisone
preparation has been tested and is now marketed in
several countries for the treatment of adrenal in-
sufficiency (415–417). This preparation combines a fast,
immediate-release surface hydrocortisone component
with a delayed-release hydrocortisone center (417). Once
daily administration of this preparation shortly after
morning awakening vs thrice daily standard hydrocor-
tisone, in addition to a very likely long-term improvement
of medication adherence, enabled a closer approximation
of the normal daytime cortisol secretory profile, as shown
in Figure 14B (415, 416). However, this dual-release
hydrocortisone does not replace the rapid rise of corti-
sol concentrations that is normally initiated after a few
hours of sleep. Nonetheless, in a study involving 64
patients with primary adrenal insufficiency, this novel
therapy translated into reduced bodyweight, reduction in
blood pressure, improved glucose homeostasis, and im-
proved quality of life (416).
Analogous to continuous sc insulin infusion in type 1
diabetes mellitus, several studies have attempted to
recreate a physiological circadian cortisol serum profile
by means of continuous pump-driven sc cortisol infusion
(418–421). Løva˚s et al (420) used continuous sc hy-
drocortisone infusion by programmable infusion pumps
in seven patients with primary adrenal insufficiency to
successfully mimic the physiological circadian cortisol
secretory rhythm, thus allowing for a considerable decrease
in hydrocortisone substitution requirements without neg-
atively impacting subjective health status. In another study,
continuous 24-hour sc hydrocortisone infusion was ef-
fective in normalizing ACTH plasma concentrations and
stabilizing circulating glucose concentrations during the
night as compared with oral hydrocortisone replacement
without impinging on endogenous insulin sensitivity as
measured by the glucose clamp technique (418). Refining
this paradigm, another study demonstrated that pulsatile,
as compared with continuous, sc hydrocortisone adminis-
tration resulted in a closer approximation of physiological
ultradian and circadian cortisol secretory profiles and
activated a specific pattern of gene transcription and
downstream neuroendocrine responses (422). An example
is shown in Figure 14C. Although pump-driven continuous
or pulsatile cortisol replacement therapy will be unlikely to
replace standard therapy for most patients with adrenal
insufficiency due to its high cost and the need for extensive
patient training in handling the infusion pump, it might
ameliorate morning symptoms in those patients who suffer
most from severe morning fatigue. This subgroup of pa-
tients is deemed to be more responsive to the absence of the
cortisol awakening response, ie, the physiological cortisol
peak shortly before awakening (423). This rise in circulating
cortisol levels cannot bemimicked by the currently available
oral hydrocortisone formulations. A delayed-release corti-
sol formulation with sustained release kinetics is currently
under development (for concise review, see Ref. 424). In
healthy subjects, administration of this preparation late at
night (15–20 mg) and in the morning (10 mg) resulted in a
close recreation of the circadian profile with very low
cortisol levels during the night, a physiological approxi-
mation of the early morning cortisol rise, resulting in a
cortisol peak around the time of waking (425) and physi-
ological cortisol profiles during the remainder of the day
(426). A very recent phase 2 study in 16 patients with
congenital adrenal hyperplasia has had encouraging re-
sults, including suppression of androgen production (427).
However, both the current and proposed hormonal re-
placement treatments using cortisol do not result in pulsatile
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GC levels, which seem to be necessary, asmentioned above,
for normal transcriptional and behavioral responses in the
target tissues.
C. Assessing central circadian phase and circadian
alignment in humans
The onset of nocturnal melatonin secretion under
dim light conditions (DLMO) is considered the most
reliable marker of the phase of the master clock. Mel-
atonin rhythms can be quantified from saliva or from
plasma samples. The total overnight melatonin output
can be estimated by measuring its urinary metabolite,
6-sulfa-toxymelatonin. A practical problem is the num-
ber of samples needed to get a reliable estimate of the phase
of the rhythm (428, 429). Protocols to estimate the DLMO
under field conditions have been developed and validated
(430). The timing of the nadir of plasma cortisol levels or
of the nadir of core body temperature under conditions of
total sleep deprivation (eliminating the masking effect of
sleep onset) are other validated markers of central circa-
dian phase, but their acquisition is clearlymore demanding
than that of the DLMO. Human fibroblasts transfected
with a lentiviral circadian reporter show in vitro rhyth-
micity, but the period is not strongly correlated with the
period of circadian behavior of the donors (431, 432).
Thus, this measure does not provide a reliable estimate of
the circadian phase of the donor. Repeated blood samples
in healthy subjects have been used to detect rhythmic ex-
pression of clock genes in blood mononuclear cells that par-
alleled hormonal and behavioral phase markers (223, 224).
The time resolution is limited by the prohibitive cost. Another
novel strategy is based on measuring rhythms of clock gene
expression using repeated sampling of hair follicles at different
time points (433), again with a limited time resolution.
The assessment of circadian alignment can be obtained
from the simultaneous examination of the 24-hour
profiles of hormones originating from different organs.
An example is the alignment of the melatonin rhythm
with the leptin rhythm, reflecting the alignment of the
central pacemaker with that of the adipocyte clock. A
more global approach consists of examining the number
of cycling genes in a given tissue. For example, in mice,
sleep restriction, by reducing the amplifying and stabi-
lizing effect of sleep on the central circadian signal, leads
to an approximately 80% reduction in the number of
transcripts that display circadian oscillations in the brain
and in a profound disruption of the liver transcriptome.
Similarly, in humans, abnormal timing of sleep causes
97%of rhythmic genes to become arrhythmic (434). This
approach, although labor-intensive and costly, could
be used to examine circadian alignment in conditions
where the 24-hour rhythm of cortisol is disturbed or
absent, as well as the efficacy of chronopharmaco-
logical replacement.
VIII. Conclusions
Among all circulating signals used by the endocrine
system, GCs are remarkable for the robustness and
complexity of their secretory dynamics. Contrasting with
other end-products of endocrine glands controlled by the
hypothalamo-pituitary axis such as T4 or IGF-I, blood
concentration of GCs does not remain at stable levels but
is constantly oscillating with both a 24-hour periodicity
and an ultradian pattern of episodic release that together
provide optimal anticipation of bodily needs and rapid
responsiveness to stressful stimuli. Optimal effects of
GCs, at the molecular as well as at the behavioral level,
occur when their rhythmic release, both circadian and
ultradian, is aligned with the dynamics of local circuits
expressing GR andMR. In addition to the direct effects of
the temporal dynamics of GC presentation to central and
peripheral tissues, the 24-hour rhythm of circulating GC
levels serves as an internal synchronizer of central and
peripheral circadian pacemakers, stabilizing the entire
circadian system of the organism. As reviewed above, the
24-hour profile of cortisol release is disrupted in a wide
variety of human conditions includingmisalignment with
the behavioral rest-activity cycle (shift work, jet lag),
dampening of the amplitude due to a failure to suppress
secretion at the habitual nocturnal nadir levels (aging,
sleep disorders, depression, and others), arrhythmic pattern
due to autonomous hypersecretion (pituitary adenoma, ad-
renal adenoma, ectopic ACTH secretion, adrenal hyper-
plasia), and suppressed endogenous levels and rhythmicity
resulting from chronic treatment with synthetic GCs or from
adrenal insufficiency, either primary or secondary. The new
understanding of the functional significance of the cortisol
rhythm for the circadian system strongly suggests that
chronopharmacological strategies that attempt to normal-
ize the rhythm of circulating GCs need to be explored for a
wide variety of physical and mental conditions and may
promote disease resistance andminimize complications and
adverse side effects of treatment. In conditions requiring
exogenousGC administration, the timing of drug treatment
should attempt to minimize the disruption of the control of
circulating cortisol levels by the central circadian pace-
maker. Further understanding of the mechanisms involved
in the synchronization of peripheral clocks by the cortisol
rhythm may lead to novel therapeutic approaches.
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